ClinicalTrials.gg
CompletedNCT02564055Updated Nov 20, 2017Results posted

A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)

A Phase 2 interventional study of GSK2894512 1% Cream and GSK2894512 0.5% Cream in Dermatitis, Atopic, sponsored by GlaxoSmithKline. Completed at 60 sites in 3 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-11-20.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing tapinarof in Dermatitis, Atopic — 1 open to participants now, 2 under way, 1 of them phase 3. tapinarof · Dermatitis, Atopic.

Enrollment
4th of 12
247 · median 168
Started
2015
with 2 others
Phase 2
3 of 12
none open now
Registered
5th of 12
by date
Lead sponsor
3 of 12
GlaxoSmithKline

Among the 12 studies testing tapinarof in Dermatitis, Atopic, this one is the 4th largest by enrollment, is one of 3 that started in 2015, is one of 3 in phase 2, and was the 5th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 12 studies testing tapinarof in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About tapinarof

tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing tapinarof in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of two concentrations (0.5 percent [%] and 1%) and two application frequencies (once a day and twice a day) of GSK2894512 cream for the topical treatment in adolescent and adult subjects with atopic dermatitis. Results from this study will be considered when selecting the most appropriate concentration of GSK2894512 cream and application frequency in future clinical studies. This is a multicenter (United States, Canada, and Japan), randomized, double-blind (sponsor-unblind), vehicle-controlled, 6-arm, parallel-group, dose-finding study in adolescent and adult subjects with atopic dermatitis. Two concentrations of GSK2894512 cream (0.5% and 1%) and a vehicle control cream will be equally randomized and evaluated following application to all atopic dermatitis lesions (except on the scalp) once daily (evening) or twice daily (morning and evening) for 12 weeks. This study will consist of 3 periods: up to 4 weeks screening, 12 weeks double-blind treatment, and 4 weeks post-treatment follow-up. The total duration of subject participation will be approximately 16 to 20 weeks. Approximately 270 adolescent and adult males and females subjects with atopic dermatitis will be screened in order to have at least 228 randomized subjects (38 subjects for each of the 6 treatment groups) and approximately 204 evaluable subjects overall. Approximately 30 subjects will be randomized in Japan to achieve at least 24 evaluable Japanese subjects.

03

Conditions studied

  • Dermatitis, Atopic

Browse trials for

Keywords

  • Vehicle-Controlled
  • GSK2894512
  • Double blind
  • Dose-finding
  • Atopic Dermatitis
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 12 and 65 years of age inclusive, at the time of signing the
  • Diagnosis of atopic dermatitis according to Hanifin and Rajka criteria and having active inflammation.
  • Body surface area involvement >=5% and \<=35%, excluding scalp, at Screening and Baseline.
  • An IGA of atopic dermatitis score of >=3 at Baseline.
  • At least one target lesion that measure at least 3 centimetre (cm) х 3 cm in size at Screening and Baseline and must be representative of the subject's disease state, but not located on the hands, feet, or genitalia.
  • A female subject is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotrophin test), not lactating, and at least one of the following conditions applies: Non- defined as: 1) Pre-menopausal females with one of the following procedures documented: tubal ligation; hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; hysterectomy; bilateral oophorectomy. 2) defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone and estradiol levels consistent with menopause and falling into the central laboratory's postmenopausal reference range is confirmatory). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt are required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment; Reproductive potential and agrees to follow one of the options listed in the modified list of highly effective methods for avoiding pregnancy in females of reproductive potential from 30 days prior to the first dose of study medication and until after the last dose of study medication and completion of the follow-up visit.

Exclusion criteria

Exclusion Criteria:

  • Unstable course of atopic dermatitis (spontaneously improving or rapidly deteriorating) as determined by the investigator over the previous 4 weeks prior to Baseline.
  • Concurrent conditions and history of other diseases: 1) Immunocompromized (eg, lymphoma, acquired immunodeficiency syndrome, Wiskott-Aldrich Syndrome) or have a history of malignant disease within 5 years before the baseline visit; 2) Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks before the baseline visit; 3) Active acute bacterial, fungal, or viral (eg, herpes simplex, herpes zoster, chicken pox) skin infection within 1 week before the baseline visit; 4) Any other concomitant skin disorder (eg, generalized erythroderma such as Netherton's Syndrome, or psoriasis); pigmentation, or extensive scarring that in the opinion of the investigator may interfere with the evaluation of AD lesions or compromise subject safety; 5) Presence of AD lesions only on the hands or feet without prior history of involvement of other classical areas of involvement such as the face or the folds; 6) Other types of eczema.
  • A history or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, may interfere with the subject's completion of the study.
  • Known to study treatment .
  • Current or chronic history of liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones), presence of surface antigen (HBsAg), or positive antibody test result within 3 months of screening.
  • Liver function tests: (ALT) >=2x (ULN); alkaline phosphatase and >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • >=450 milliseconds (msec) or QTc >=480 msec for subjects with bundle branch block.

NOTES: The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF), with machine over-read. The QTc should be based on a single obtained over a brief recording period. If QTc is outside of the threshold value, triplicate ECGs may be performed with the QTc values averaged.

  • Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation (eg, sunlight or tanning booth) within 4 weeks prior to the baseline visit and/or intention to have such exposure during the study, which is thought by the investigator to potentially impact the subject's atopic dermatitis.
  • Used any of the following treatments within the indicated before the baseline visit: 12 weeks or 5 half-lives (whichever is longer) - biologic agents (eg, 18 weeks for omalizumab); 8 weeks - cyclosporin, methotrexate, azathioprine, or other systemic or immunomodulating agents (eg, mycophenolate or tacrolimus); 4 weeks - systemic or adrenocorticotropic hormone analogs; 2 weeks - topical treatments: corticosteroids, calcineurin inhibitors, or coal tar (on the body); 2 weeks - immunizations; sedating antihistamines (non sedating antihistamines are permitted); 1 week - topical antibiotics, antibacterial cleansing body wash/soap or diluted sodium hypochlorite "bleach" baths.
  • Participated in a clinical study and received an product within the following time period prior to the baseline visit: 4 weeks, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer).
  • History of alcohol or other substance abuse within the last 2 years.
  • Participated in a previous study using GSK2894512 (or WBI-1001).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    GSK2894512 1% cream twice daily

    Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram \[mg/g\]) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).

    Drug: GSK2894512 1% Cream

  • Experimental
    GSK2894512 1% cream once daily

    Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).

    Drug: GSK2894512 1% Cream

  • Experimental
    GSK2894512 0.5% cream twice daily

    Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).

    Drug: GSK2894512 0.5% Cream

  • Experimental
    GSK2894512 0.5% cream once daily

    Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).

    Drug: GSK2894512 0.5% Cream

  • Placebo comparator
    Vehicle cream twice daily

    Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).

    Drug: Vehicle cream

  • Placebo comparator
    Vehicle cream once daily

    Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).

    Drug: Vehicle cream

Interventions

  • 1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically

  • 0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically

  • DrugVehicle cream

    White to off-white vehicle cream base to be applied topically

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Have an Investigator Global Assessment (IGA) Score of Clear or Almost Clear (0 or 1) at Week 12 and a Minimum 2 Grade Improvement in IGA Score From Baseline to Week 12 for Intent to Treat (ITT) Population

    The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. The percentage of participants who have an IGA score of clear or almost clear at Week 12 and a minimum 2 grade improvement from Baseline to Week 12 in IGA score was presented. . The analysis was performed on ITT Population which comprised of all randomized participants.

    Time frame: Baseline and up to Week 12

Secondary outcomes

  1. Mean Change From Baseline in Weekly Average of Daily Itch/Pruritus (Numeric Rating Scale [NRS]) Score

    NRS is a 11-point tool ranging from 0 (absent) to 10 (worst imaginable) to assess the severity of 11 disease-related signs and symptoms including itching, discoloration, bleeding, oozing, cracking, scaling, flaking, dry/rough, painful, burning, and stinging. Participants were asked to complete the self-administered sign and symptom severity diary containing NRS using a recall period of the past 24 hours. Question 1 of the diary was used to assess itch. Mean change from Baseline to Week 12 in weekly average of daily itch/pruritus based on the NRS was presented using mean and standard deviation (SD). Baseline was defined as the latest assessment prior to first dose and Change from Baseline was defined as post-dose weekly average value minus Baseline value.

    Time frame: Baseline and up to Week 12

  2. Mean Percent Change From Baseline in Weekly Average of Daily Itch/Pruritus NRS Score

    NRS is a 11-point tool ranging from 0 (absent) to 10 (worst imaginable) to assess the severity of 11 disease-related signs and symptoms including itching, discoloration, bleeding, oozing, cracking, scaling, flaking, dry/rough, painful, burning, and stinging. Participants were asked to complete the self-administered sign and symptom severity diary containing NRS using a recall period of the past 24 hours. Question 1 of the diary was used to assess itch. Mean percent change in weekly average of daily itch/pruritus based on the NRS was presented using mean and SD from Baseline to Week 12. Baseline was defined as the latest assessment prior to first dose and Change from Baseline was defined as post-dose weekly average value minus Baseline value.

    Time frame: Baseline and up to Week 12

  3. Percentage of Participants Who Achieve a Minimum 3- Point Improvement in Itch/Pruritus (NRS) From Baseline to Each Study Visit

    NRS is a 11-point tool ranging from 0 (absent) to 10 (worst imaginable) to assess the severity of 11 disease-related signs and symptoms including itching, discoloration, bleeding, oozing, cracking, scaling, flaking, dry/rough, painful, burning, and stinging. Participants were asked to complete the self-administered sign and symptom severity diary containing NRS using a recall period of the past 24 hours. Question 1 of the diary was used to assess itch. Percentage of participants who achieved a minimum 3-point improvement in itch/pruritus (NRS) from Baseline to each study visit were measured. Baseline was defined as the latest assessment prior to first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

    Time frame: Week 1, 2, 4, 8, 12, 14, 16, early withdrawal (EW) (up to Week 16)

  4. Mean Change From Baseline in Eczema Area and Severity Index (EASI) Score

    The EASI scoring system is a standard clinical tool for assessing the severity of AD that takes into account the overall severity of erythema, infiltration/papulation, excoriation, and lichenification, as well as the extent of BSA affected with AD. These 4 clinical signs were graded on a 4-point scale (0 \[absent\] to 3 \[severe\]) for each of the 4 specified body regions (head and neck, upper extremities, lower extremities, and trunk). Body area involvement ranged from 0 (0%) to 6 (90-100%). Total EASI score was calculated as a sum of scores of all 4 specified body region. Range for EASI total score is 0 (absent) to 72 (severe). Baseline was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Mean change from Baseline was presented in the form of mean and SD. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Week 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)

  5. Mean Percent Change From Baseline in EASI Score

    The EASI scoring system is a standard clinical tool for assessing the severity of AD that takes into account the overall severity of erythema, infiltration/papulation, excoriation, and lichenification, as well as the extent of BSA affected with AD. These 4 clinical signs were graded on a 4-point scale (0 \[absent\] to 3 \[severe\]) for each of the 4 specified body regions (head and neck, upper extremities, lower extremities, and trunk). Body area involvement ranged from 0 (0%) to 6 (90-100%). Total EASI score was calculated as a sum of scores of all 4 specified body region. Range for EASI total score is 0 (absent) to 72 (severe). Baseline was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Mean percent change from Baseline was presented in the form of mean and SD. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)

  6. Percentage of Participants With a Minimum 2-grade Improvement in IGA Score From Baseline to Each Visit

    The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. IGA is made without reference to previous scores. The percentage of participants with a minimum 2-grade improvement in IGA score from Baseline at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and early withdrawal (EW) visit was presented in the form of mean and SD. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)

  7. Percentage of Participants With an IGA Score of 0 or 1 at Each Visit

    The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. IGA is made without reference to previous scores. The percentage of participants with an IGA score of 0 or 1 at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit was presented in the form of mean and SD. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)

  8. Percentage of Participants With >=50 Percent Improvement From Baseline in EASI

    The EASI scoring system is a standard clinical tool for assessing the severity of AD that takes into account the overall severity of erythema, infiltration/papulation, excoriation, and lichenification, as well as the extent of BSA affected with AD. These 4 clinical signs were graded on a 4-point scale for each of the 4 specified body regions (head and neck, upper extremities, lower extremities, and trunk). Percentage of participants with \>=50 percent improvement in EASI score from Baseline to Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW were presented and statistical analysis was performed using a repeated measures factorial logistic regression model. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)

  9. Percentage of Participants With >=75 Percent Improvement From Baseline in EASI

    The EASI scoring system is a standard clinical tool for assessing the severity of AD that takes into account the overall severity of erythema, infiltration/papulation, excoriation, and lichenification, as well as the extent of BSA affected with AD. These 4 clinical signs were graded on a 4-point scale for each of the 4 specified body regions (head and neck, upper extremities, lower extremities, and trunk). Percentage of participants with \>=75 percent improvement in EASI score from Baseline to Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW were presented and statistical analysis was performed using a repeated measures factorial logistic regression model. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)

  10. Mean Change From Baseline in Total Severity Score (TSS)

    A target lesion of at least 3 centimeter square (cm\^2) was selected at Baseline. The severity of the following signs: erythema, induration/papulation, lichenification, oozing/crusting, and scaling was assessed on a 4-point scale ranging from 0 (absent) to 3 (severe), with higher values indicating greater severity of symptoms. TSS (maximum score 15) was calculated based on these signs. Mean change from Baseline in TSS at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit was presented using mean and SD. Baseline value was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)

  11. Mean Percent Change From Baseline in TSS

    A target lesion of at least 3 cm\^2 was selected at Baseline. The severity of the following signs: erythema, induration/papulation, lichenification, oozing/crusting, and scaling was assessed on a 4-point scale ranging from 0 (absent) to 3 (severe) , with higher values indicating greater severity of symptoms. TSS (maximum score 15) was calculated based on these signs. Mean percent change from Baseline in TSS at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit was presented using mean and SD. Baseline value was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Week 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)

  12. Mean Change From Baseline in Individual Signs of TSS

    The severity of the following signs: erythema, induration/papulation, lichenification, oozing/crusting, and scaling was assessed on a 4-point scale ranging from 0 (absent) to 3 (severe) and TSS (maximum score 15) was calculated based on these signs. Mean change from Baseline in individual signs of TSS was presented using mean and SD. Baseline value was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. If the participant had more than 3 missing days during the week, then the weekly average was not calculated and treated as missing data and excluded from the analysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)

  13. Mean Percent Change From Baseline in Individual Signs of TSS

    The severity of the following signs: erythema, induration/papulation, lichenification, oozing/crusting, and scaling was assessed on a 4-point scale ranging from 0 (absent) to 3 (severe) and TSS (maximum score 15) was calculated based on these signs. Mean percent change from Baseline in individual signs of TSS was presented using mean and SD. Baseline value was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. NA indicates that data were not available. If the participant had more than 3 missing days during the week, then the weekly average was not calculated and treated as missing data and excluded from the analysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Week 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)

  14. Mean Change From Baseline in Body Surface Area (Percent BSA)

    The extent of BSA affected by AD is a general indicator of disease severity and the assessment of BSA with AD was performed separately for four body surface regions: the head (h), the upper extremities (u), the trunk (t) and the lower extremities (l), corresponding to 10, 20, 30, and 40 percent of the total body area, respectively. Mean change from Baseline in percent BSA was presented using mean and SD at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit. Baseline was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)

  15. Mean Change From Baseline in IGA Score

    The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. IGA is made without reference to previous scores. Score ranges from 0 (clear) to 4 (severe). Higher values represent a severe disease. Mean change from Baseline in IGA score was presented using mean and SD at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit. Baseline was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)

  16. Percentage of Participants Who Have an IGA Score of Clear or Almost Clear (0 or 1) and a Minimum 2 Grade Improvement in IGA Score From Baseline to Each Study Visit

    The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. IGA is made without reference to previous scores. The percentage of participants who have an IGA score of clear or almost clear and a minimum 2 grade improvement from Baseline to each study visit in IGA score was presented. The statistical analysis was performed using a repeated measures factorial logistic regression model with covariates for dose, frequency of administration, and study day as well as a dose by frequency interaction term. The analysis was performed on ITT Population which comprised of all randomized participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category title).

    Time frame: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to week 16)

  17. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function. Treatment emergent AEs (TEAE) is defined as AE occurred on or after study treatment start date and on or before last visit. Number of participants with AEs and serious TEAEs were presented. The analysis was performed on Safety population which comprised of all participants who receive at least one dose of study treatment.

    Time frame: Weeks 1, 2, 4, 8, 12, 14, EW (up to week 14)

  18. Number of Participants With Reported Tolerability Score of 0 to 4 Over Time

    Participants were asked to use a 5-point tolerability scale from 0 (none) to 4 (severe) to assess the presence and degree of burning/stinging and itching at the application sites that has generally been experienced following application of the study treatment. The score represented an 'average' across all application sites. A score of 3 or 4 was reported as an AE. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Week 1, 2, 4, 8, 12, 14, EW (up to Week 14)

  19. Change From Baseline in Albumin and Total Protein

    Blood samples were collected to evaluate change from Baseline in albumin and total protein values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

    Time frame: Week 1, 2, 4, 8, 12, 14, EW (up to week 14)

  20. Change From Baseline in Alkaline Phosphatase (Alk.Phosph.), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Gamma Glutamyl Transferase (GGT)

    Blood samples were collected to evaluate change from Baseline in Alk.phosph., ALT, AST and GGT values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

    Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)

  21. Change From Baseline in Direct and Total Bilirubin, Creatinine and Urate

    Blood samples were collected to evaluate change from Baseline in direct and total bilirubin, creatinine and urate values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

    Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)

  22. Change From Baseline in Calcium, Chloride, Carbon Dioxide (CO2), Glucose, Potassium, Sodium, Blood Urea Nitrogen (BUN)

    Blood samples were collected to evaluate change from Baseline in calcium, chloride, CO2, glucose, potassium, sodium and BUN values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

    Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)

  23. Number of Participants With Chemistry Data of Potential Clinical Importance

    Blood samples were collected from participants for evaluation of clinical chemistry parameters by Potential Clinical Importance Criteria from Baseline to Week 14, EW and any visit post-screen. The vital signs included alk.phosph., ALT, AST, bilirubin, calcium, CO2, creatinine, glucose and potassium. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

    Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)

  24. Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet, Leukocytes Count

    Blood samples were collected to evaluate change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet and leukocytes and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

    Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)

  25. Change From Baseline in Hematocrit Levels

    Blood samples were collected to evaluate change from Baseline in hematocrit and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

    Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)

  26. Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC)

    Blood samples were collected to evaluate change from Baseline in hemoglobin and MCHC and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

    Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)

  27. Change From Baseline in Mean Corpuscle Hemoglobin (MCH)

    Blood samples were collected to evaluate change from Baseline in MCH and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

    Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)

  28. Change From Baseline in Mean Corpuscle Volume (MCV)

    Blood samples were collected to evaluate change from Baseline in MCV and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

    Time frame: Week 2, 4, 8, 12, 14, EW (up to week 14)

  29. Change From Baseline in Erythrocyte Count

    Blood samples were collected to evaluate change from Baseline in erythrocytes and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

    Time frame: Weeks 2, 4, 8, 12, 14, EW (week up to 14)

  30. Number of Participants With Hematology Data of Potential Clinical Importance

    Blood samples were collected from participants for evaluation of hematology parameters by Potential Clinical Importance Criteria from Baseline to Week 14, EW and any visit post-screen. The vital signs included hematocrit, hemoglobin, lymphocytes, neutrophils, platelet and leukocytes. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

    Time frame: Baseline, Week 2, 4, 8, 12, 14, early withdrawal, and post screen (up to Week 16)

  31. Change From Baseline in Total T Lymphocytes (Lympho), B Lympho, Natural Killer (NK) Lymphocytes and Treg (Foxp3) Levels

    Blood samples were collected to evaluate change from Baseline in total T lympho, B lympho, T and B NK cells and (Foxp3) values at Baseline throughout the 12 weeks of study treatment. The immunophenotyping parameters included cluster of differentiation (CD)19, CD3, CD3+CD8+, CD3+CD4+, CD16+CD56+, CD3+CD4+CD25+CD127, CD3+CD4+foxP3+CD25+CD127 and T and NK lympho. CD3, CD3+CD8+ and CD3+CD4+ were also evaluated by using treg flow cytometry (cyto). Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

    Time frame: Week, 4, 8 and 12

  32. Number of Participants With Immunopheotyping Data Outside the Reference Range

    Blood samples were collected from participants for evaluation of immunophenotyping parameters by Potential Clinical Importance Criteria at Baseline, Week 4, Week 8, Week 12 nd any visit post-screen. The immunophenotyping parameters included CD 19, CD3, CD3+CD8+, CD3+CD4+, CD16+CD56+, CD3+CD4+CD25+CD127, CD3+CD4+foxP3+CD25+CD127 and T and NK lympho. CD3, CD3+CD8+ and CD3+CD4+ were also evaluated by using treg flow cyto. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

    Time frame: Baseline, Week, 4, 8, 12 and post-screen (up to Week 16)

  33. Change From Baseline in Immunoglobin (Ig) A, IgG and IgM Levels

    Blood samples were collected to evaluate change from Baseline in IgA, IgG, IM values at Baseline throughout the 12 weeks of study treatment. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

    Time frame: Week, 4, 8 and 12

  34. Number of Participants With Immunoglobulin Data Outside the Reference Range

    Blood samples were collected from participants for evaluation of immunoglobulin data outside the reference range at Baseline, Week 4, Week 8, Week 12 and any visit post-screen. The immunoglobulin parameters included IgA, IgG and Ig M. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

    Time frame: Baseline, Week, 4, 8, 12, post-screen (up to Week 16)

  35. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    SBP and DBP were measured from Baseline up to follow up Visit 1 at Week 14 in semi-supine position after at least 5 minutes of rest. The Baseline value was taken at Day 1 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

    Time frame: Week 1, 2, 4, 8, 12, 14, EW (up to week 14)

  36. Change From Baseline in Pulse Rate

    Pulse rate were measured from Baseline up to follow up Visit 1 at Week 14 in semi-supine position after at least 5 minutes of rest. The Baseline value was taken at Day 1 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

    Time frame: Week 1, 2, 4, 8, 12, 14, EW (up to week 14)

  37. Change From Baseline in Temperature

    Temperature were measured from Baseline up to follow up Visit 1 at Week 14 in semi-supine position after at least 5 minutes of rest. The Baseline value was taken at Day 1 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

    Time frame: Week 1, 2, 4, 8, 12, 14, EW (up to week 14)

  38. Number of Participants With Vital Signs of Potential Clinical Importance

    Blood samples were collected from participants for evaluation of vital signs by Potential Clinical Importance Criteria from Baseline to Week 14, EW and any visit post-screen. The vital signs included SBP, DBP and pulse rate. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

    Time frame: Baseline, Week 2, 4, 8, 12, 14, EW (up to week 14)

  39. Number of Participants With Abnormal Electrocardiogram (ECG) Findings

    Single measurements of 12-lead ECGs were obtained at Baseline , Week 1, Week 12, Week 14 (follow up 1), EW and at any time post-screen using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc). Baseline was defined as the latest assessment prior to the first dose. For multiple ECGs at one visit, or "Any visit post-screen", a participant was categorized as "Abnormal" if \>=1 assessment was abnormal. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline, Week 1, 12, 14, EW ( up to Week 14), post-screen

07

Results

Posted Nov 20, 2017

Participant flow

Eligible participants entered a 4 weeks screening phase and participants who met the eligibility criteria entered into the 12 weeks double-blind treatment phase and 4 weeks post-treatment follow-up phase. The total duration of participation in the study was 16 to 20 weeks.

Participant flow — Overall Study
MilestoneGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Started404143414240
Completed343631352728
Not completed651261512
Withdrew: Adverse event104141
Withdrew: Protocol violation100000
Withdrew: Reached stopping criteria000001
Withdrew: Lost to follow-up014210
Withdrew: Physician decision001000
Withdrew: Withdrawal by subject44331010

Outcome measures

PrimaryPercentage of Participants Who Have an Investigator Global Assessment (IGA) Score of Clear or Almost Clear (0 or 1) at Week 12 and a Minimum 2 Grade Improvement in IGA Score From Baseline to Week 12 for Intent to Treat (ITT) Population

The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. The percentage of participants who have an IGA score of clear or almost clear at Week 12 and a minimum 2 grade improvement from Baseline to Week 12 in IGA score was presented. . The analysis was performed on ITT Population which comprised of all randomized participants.

Time frame:
Baseline and up to Week 12
Reported as:
Number · Percentage of participant
Percentage of Participants Who Have an Investigator Global Assessment (IGA) Score of Clear or Almost Clear (0 or 1) at Week 12 and a Minimum 2 Grade Improvement in IGA Score From Baseline to Week 12 for Intent to Treat (ITT) Population
Percentage of participantGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Percentage of Participants Who Have an Investigator Global Assessment (IGA) Score of Clear or Almost Clear (0 or 1) at Week 12 and a Minimum 2 Grade Improvement in IGA Score From Baseline to Week 12 for Intent to Treat (ITT) Population585150403644
Statistical analysis
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 22.6 · 95% CI -2.4 to 45.5Difference between GSK2894512 1 percent BID and Vehicle BID has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 7.4 · 95% CI -18.3 to 32.0Difference between GSK2894512 1 percent QD and Vehicle QD has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: 14.3 · 95% CI -11.2 to 38.7Difference between GSK2894512 0.5 percent BID and Vehicle BID has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: -4.0 · 95% CI -29.3 to 21.6Difference between GSK2894512 0.5 percent QD and Vehicle QD has been presented.
SecondaryMean Change From Baseline in Weekly Average of Daily Itch/Pruritus (Numeric Rating Scale [NRS]) Score

NRS is a 11-point tool ranging from 0 (absent) to 10 (worst imaginable) to assess the severity of 11 disease-related signs and symptoms including itching, discoloration, bleeding, oozing, cracking, scaling, flaking, dry/rough, painful, burning, and stinging. Participants were asked to complete the self-administered sign and symptom severity diary containing NRS using a recall period of the past 24 hours. Question 1 of the diary was used to assess itch. Mean change from Baseline to Week 12 in weekly average of daily itch/pruritus based on the NRS was presented using mean and standard deviation (SD). Baseline was defined as the latest assessment prior to first dose and Change from Baseline was defined as post-dose weekly average value minus Baseline value.

Time frame:
Baseline and up to Week 12
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Weekly Average of Daily Itch/Pruritus (Numeric Rating Scale [NRS]) Score
Scores on a scaleGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Mean Change From Baseline in Weekly Average of Daily Itch/Pruritus (Numeric Rating Scale [NRS]) Score-3.06 ± 2.657-3.10 ± 2.493-3.52 ± 2.307-3.39 ± 2.297-0.95 ± 2.107-3.50 ± 2.742
SecondaryMean Percent Change From Baseline in Weekly Average of Daily Itch/Pruritus NRS Score

NRS is a 11-point tool ranging from 0 (absent) to 10 (worst imaginable) to assess the severity of 11 disease-related signs and symptoms including itching, discoloration, bleeding, oozing, cracking, scaling, flaking, dry/rough, painful, burning, and stinging. Participants were asked to complete the self-administered sign and symptom severity diary containing NRS using a recall period of the past 24 hours. Question 1 of the diary was used to assess itch. Mean percent change in weekly average of daily itch/pruritus based on the NRS was presented using mean and SD from Baseline to Week 12. Baseline was defined as the latest assessment prior to first dose and Change from Baseline was defined as post-dose weekly average value minus Baseline value.

Time frame:
Baseline and up to Week 12
Reported as:
Mean · Percentage Change
Mean Percent Change From Baseline in Weekly Average of Daily Itch/Pruritus NRS Score
Percentage ChangeGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Mean Percent Change From Baseline in Weekly Average of Daily Itch/Pruritus NRS Score-64.69 ± 36.916-58.34 ± 45.632-60.39 ± 44.314-61.40 ± 34.958-29.16 ± 55.251-55.62 ± 40.320
SecondaryPercentage of Participants Who Achieve a Minimum 3- Point Improvement in Itch/Pruritus (NRS) From Baseline to Each Study Visit

NRS is a 11-point tool ranging from 0 (absent) to 10 (worst imaginable) to assess the severity of 11 disease-related signs and symptoms including itching, discoloration, bleeding, oozing, cracking, scaling, flaking, dry/rough, painful, burning, and stinging. Participants were asked to complete the self-administered sign and symptom severity diary containing NRS using a recall period of the past 24 hours. Question 1 of the diary was used to assess itch. Percentage of participants who achieved a minimum 3-point improvement in itch/pruritus (NRS) from Baseline to each study visit were measured. Baseline was defined as the latest assessment prior to first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Time frame:
Week 1, 2, 4, 8, 12, 14, 16, early withdrawal (EW) (up to Week 16)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieve a Minimum 3- Point Improvement in Itch/Pruritus (NRS) From Baseline to Each Study Visit
Percentage of ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1; n= 29,35,33,31,24,25249916812
Week 2; n= 28,30,36,30,26,23363322331222
Week 4; n= 31,31,29,31,20,25424845523528
Week 8; n= 26,26,29,30,21,23465048572930
Week 12; n= 22,25,23,23,14,16555261521438
Week 14; n= 21,20,19,20,17,14384058502950
Week 16; n= 15,14,22,17,12,13332141471723
EW; n= 0,3,2,2,5,6—05050017
SecondaryMean Change From Baseline in Eczema Area and Severity Index (EASI) Score

The EASI scoring system is a standard clinical tool for assessing the severity of AD that takes into account the overall severity of erythema, infiltration/papulation, excoriation, and lichenification, as well as the extent of BSA affected with AD. These 4 clinical signs were graded on a 4-point scale (0 \[absent\] to 3 \[severe\]) for each of the 4 specified body regions (head and neck, upper extremities, lower extremities, and trunk). Body area involvement ranged from 0 (0%) to 6 (90-100%). Total EASI score was calculated as a sum of scores of all 4 specified body region. Range for EASI total score is 0 (absent) to 72 (severe). Baseline was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Mean change from Baseline was presented in the form of mean and SD. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Week 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Eczema Area and Severity Index (EASI) Score
Scores on a scaleGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1; n= 38,41,39,37,38,32-2.58 ± 3.965-3.83 ± 4.410-3.22 ± 3.585-2.51 ± 3.240-1.84 ± 2.730-1.06 ± 3.660
Week 2; n= 39,39,39,39,33,32-4.89 ± 4.052-5.69 ± 3.996-5.27 ± 3.848-4.21 ± 3.337-3.18 ± 3.545-1.67 ± 3.079
Week 4; n= 38,39,38,39,30,32-6.55 ± 3.808-7.18 ± 4.534-7.42 ± 3.749-6.19 ± 3.588-4.45 ± 4.180-2.94 ± 3.788
Week 8; n= 36,37,34,38,29,27-7.00 ± 4.759-8.12 ± 4.924-8.67 ± 5.039-7.62 ± 4.539-5.24 ± 5.267-4.15 ± 5.190
Week 12; n= 36,37,32,35,28,25-7.85 ± 5.000-8.16 ± 4.931-10.12 ± 4.665-8.16 ± 5.077-6.05 ± 5.937-5.58 ± 5.668
Week 14; n= 34,35,31,33,27,25-7.08 ± 3.955-7.36 ± 4.683-9.07 ± 5.367-7.42 ± 4.798-6.28 ± 5.335-5.44 ± 5.050
Week 16; n= 34,36,31,35,27,25-6.45 ± 4.245-7.45 ± 5.106-8.85 ± 5.654-7.67 ± 4.405-6.29 ± 6.158-5.40 ± 5.315
EW; n= 3,4,7,3,11,11-1.03 ± 5.5233.40 ± 4.0233.11 ± 9.042-2.97 ± 6.6612.01 ± 4.4183.38 ± 9.746
SecondaryMean Percent Change From Baseline in EASI Score

The EASI scoring system is a standard clinical tool for assessing the severity of AD that takes into account the overall severity of erythema, infiltration/papulation, excoriation, and lichenification, as well as the extent of BSA affected with AD. These 4 clinical signs were graded on a 4-point scale (0 \[absent\] to 3 \[severe\]) for each of the 4 specified body regions (head and neck, upper extremities, lower extremities, and trunk). Body area involvement ranged from 0 (0%) to 6 (90-100%). Total EASI score was calculated as a sum of scores of all 4 specified body region. Range for EASI total score is 0 (absent) to 72 (severe). Baseline was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Mean percent change from Baseline was presented in the form of mean and SD. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Reported as:
Mean · Percentage Change
Mean Percent Change From Baseline in EASI Score
Percentage ChangeGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1; n= 38,41,39,37,38,32-23.83 ± 42.885-34.76 ± 32.718-24.19 ± 21.716-25.81 ± 28.724-16.79 ± 25.777-7.51 ± 36.549
Week 2; n= 39,39,39,39,33,32-48.70 ± 33.089-54.21 ± 29.107-42.60 ± 26.428-40.41 ± 30.835-32.03 ± 32.737-13.98 ± 38.616
Week 4; n= 38,39,38,39,30,32-64.95 ± 23.948-66.40 ± 30.182-60.07 ± 23.967-55.38 ± 24.465-40.74 ± 30.097-30.54 ± 36.196
Week 8; n= 36,37,34,38,29,27-68.14 ± 28.052-73.57 ± 27.204-70.52 ± 25.062-65.12 ± 26.089-50.78 ± 33.026-43.15 ± 41.388
Week 12; n= 36,37,32,35,28,25-77.19 ± 28.152-73.02 ± 25.068-80.13 ± 18.602-69.49 ± 24.805-56.73 ± 38.234-60.29 ± 34.253
Week 14; n= 34,35,31,33,27,25-71.15 ± 27.875-65.53 ± 29.777-70.37 ± 31.907-64.72 ± 25.594-60.26 ± 31.632-55.21 ± 31.514
Week 16; n= 34,36,31,35,27,25-63.59 ± 36.461-63.70 ± 25.833-69.89 ± 32.687-67.28 ± 25.745-57.52 ± 47.140-52.47 ± 38.236
EW; n= 3,4,7,3,11,11-0.83 ± 98.75342.27 ± 43.9508.74 ± 87.714-35.40 ± 66.34913.69 ± 32.42432.55 ± 86.387
SecondaryPercentage of Participants With a Minimum 2-grade Improvement in IGA Score From Baseline to Each Visit

The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. IGA is made without reference to previous scores. The percentage of participants with a minimum 2-grade improvement in IGA score from Baseline at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and early withdrawal (EW) visit was presented in the form of mean and SD. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Reported as:
Number · Percentage of participants
Percentage of Participants With a Minimum 2-grade Improvement in IGA Score From Baseline to Each Visit
Percentage of participantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1; n= 38,41,39,37,38,32570356
Week 2; n= 39, 39, 39, 39, 33, 3218211015159
Week 4; n= 38,39,38,39,30,32324626282313
Week 8; n= 36,37,34,38,29,27445938452822
Week 12; n= 36,37,32,35,28,25645153433944
Week 14; n= 34,35,31,33,27,25474655422636
Week 16; n= 34,36,31,35,27,25353639433332
EW; n= 3,4,7,3,11,11330143309
SecondaryPercentage of Participants With an IGA Score of 0 or 1 at Each Visit

The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. IGA is made without reference to previous scores. The percentage of participants with an IGA score of 0 or 1 at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit was presented in the form of mean and SD. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Reported as:
Number · Percentage of participants
Percentage of Participants With an IGA Score of 0 or 1 at Each Visit
Percentage of participantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1; 38,41,39,37,38,32550333
Week 2; n= 39,39,39,39,33,3218181013159
Week 4; n= 38,39,38,39,30,3232382623209
Week 8; n= 36,37,34,38,29,27425438422819
Week 12; n= 36,37,32,35,28,25585150403644
Week 14; n= 34,35,31,33,27,25444352362636
Week 16; n= 34,36,31,35,27,25353639403028
EW; n= 3,4,7,3,11,11330143309
SecondaryPercentage of Participants With >=50 Percent Improvement From Baseline in EASI

The EASI scoring system is a standard clinical tool for assessing the severity of AD that takes into account the overall severity of erythema, infiltration/papulation, excoriation, and lichenification, as well as the extent of BSA affected with AD. These 4 clinical signs were graded on a 4-point scale for each of the 4 specified body regions (head and neck, upper extremities, lower extremities, and trunk). Percentage of participants with \>=50 percent improvement in EASI score from Baseline to Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW were presented and statistical analysis was performed using a repeated measures factorial logistic regression model. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Reported as:
Number · Percentage of participants
Percentage of Participants With >=50 Percent Improvement From Baseline in EASI
Percentage of participantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1; n= 38, 41, 39, 37, 38, 32323913221113
Week 2; n= 39, 39, 39, 39, 33, 32565638363319
Week 4; n= 38, 39, 38, 39, 30, 32767263593741
Week 8; n= 36, 37, 34, 38, 29, 27819285795956
Week 12; n= 36, 37, 32, 35, 28, 25838497746484
Week 14; n= 34, 35, 31, 33, 27, 25857481766368
Week 16; n= 34, 36, 31 35, 27, 25767884716772
EW; n= 3,4,7,3,11,11330293309
Statistical analysis
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 21.1 · 95% CI -2.7 to 43.1Difference between GSK2894512 1 % BID and Vehicle BID at Week 1 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 26.5 · 95% CI 3.3 to 47.5Difference between GSK2894512 1 % QD and Vehicle QD at Week 1 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: 2.3 · 95% CI -19.5 to 24.5Difference between GSK2894512 0.5 % BID and Vehicle BID at Week 1 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: 9.1 · 95% CI -14.5 to 32.0Difference between GSK2894512 0.5 % QD and Vehicle QD at Week 1 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 23.1 · 95% CI -0.3 to 44.6Difference between GSK2894512 1 % BID and Vehicle BID at Week 2 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 37.7 · 95% CI 14.7 to 57.6Difference between GSK2894512 1 % QD and Vehicle QD at Week 2 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: 5.1 · 95% CI -18.0 to 27.8Difference between GSK2894512 0.5 % BID and Vehicle BID at Week 2 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: 17.1 · 95% CI -6.4 to 39.0Difference between GSK2894512 0.5 % QD and Vehicle QD at Week 2 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 39.6 · 95% CI 16.0 to 60.0Difference between GSK2894512 1 % BID and Vehicle BID at Week 4 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 31.2 · 95% CI 7.8 to 52.1Difference between GSK2894512 1 % QD and Vehicle QD at Week 4 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: 26.5 · 95% CI 2.3 to 48.4Difference between GSK2894512 0.5 % BID and Vehicle BID at Week 4 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: 18.3 · 95% CI -5.3 to 40.5Difference between GSK2894512 0.5 % QD and Vehicle QD at Week 4 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 21.9 · 95% CI -2.3 to 44.7Difference between GSK2894512 1 % BID and Vehicle BID at Week 8 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 36.3 · 95% CI 12.1 to 57.6Difference between GSK2894512 1 % QD and Vehicle QD at Week 8 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: 26.7 · 95% CI 1.7 to 49.0Difference between GSK2894512 0.5 % BID and Vehicle BID at Week 8 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: 23.4 · 95% CI -1.5 to 46.1Difference between GSK2894512 0.5 % QD and Vehicle QD at Week 8 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 19.0 · 95% CI -6.0 to 42.3Difference between GSK2894512 1 % BID and Vehicle BID at Week 12 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: -0.2 · 95% CI -25.0 to 25.0Difference between GSK2894512 1 % QD and Vehicle QD at Week 12 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: 32.6 · 95% CI 6.9 to 55.0Difference between GSK2894512 0.5 % BID and Vehicle BID at Week 12 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: -9.7 · 95% CI -34.6 to 16.1Difference between GSK2894512 0.5 % QD and Vehicle QD at Week 12 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 22.3 · 95% CI -3.1 to 45.3Difference between GSK2894512 1 % BID and Vehicle BID at Week 14 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 6.3 · 95% CI -19.5 to 31.5Difference between GSK2894512 1 % QD and Vehicle QD at Week 14 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: 17.7 · 95% CI -8.4 to 41.9Difference between GSK2894512 0.5 % BID and Vehicle BID at Week 14 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: 7.8 · 95% CI -17.8 to 33.1Difference between GSK2894512 0.5 % QD and Vehicle QD at Week 14 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 9.8 · 95% CI -15.5 to 33.9Difference between GSK2894512 1 % BID and Vehicle BID at Week 16 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 5.8 · 95% CI -19.7 to 30.5Difference between GSK2894512 1 % QD and Vehicle QD at Week 16 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: 17.2 · 95% CI -9.0 to 41.4Difference between GSK2894512 0.5 % BID and Vehicle BID at Week 16 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: -0.6 · 95% CI -26.0 to 25.0Difference between GSK2894512 0.5 % QD and Vehicle QD at Week 16 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 33.3 · 95% CI -31.9 to 90.6Difference between GSK2894512 1 % BID and Vehicle BID at EW has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: -9.1 · 95% CI -62.4 to 47.8Difference between GSK2894512 1 % QD and Vehicle QD at EW has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: 28.6 · 95% CI -19.2 to 71.0Difference between GSK2894512 0.5 % BID and Vehicle BID at EW has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: 24.2 · 95% CI -40.3 to 80.9Difference between GSK2894512 0.5 % QD and Vehicle QD at EW has been presented.
SecondaryPercentage of Participants With >=75 Percent Improvement From Baseline in EASI

The EASI scoring system is a standard clinical tool for assessing the severity of AD that takes into account the overall severity of erythema, infiltration/papulation, excoriation, and lichenification, as well as the extent of BSA affected with AD. These 4 clinical signs were graded on a 4-point scale for each of the 4 specified body regions (head and neck, upper extremities, lower extremities, and trunk). Percentage of participants with \>=75 percent improvement in EASI score from Baseline to Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW were presented and statistical analysis was performed using a repeated measures factorial logistic regression model. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Reported as:
Number · Percentage of participants
Percentage of Participants With >=75 Percent Improvement From Baseline in EASI
Percentage of participantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1; n= 38, 41, 39, 37, 38, 325120506
Week 2; n= 39, 39, 39, 39, 33, 322133132193
Week 4; n= 38, 39, 38, 39, 30, 3237512926209
Week 8; n= 36, 37, 34, 38, 29, 27445753373126
Week 12; n= 36, 37, 32, 35, 28, 25675769463940
Week 14; n= 34, 35, 31, 33, 27, 25504968364136
Week 16; n= 34, 36, 31 35, 27, 25473961434432
EW; n= 3,4,7,3,11,11330143309
Statistical analysis
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 5.3 · 95% CI -18.3 to 28.4Difference between GSK2894512 1 % BID and Vehicle BID at Week 1 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 5.9 · 95% CI -17.1 to 28.4Difference between GSK2894512 1 % QD and Vehicle QD at Week 1 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: -0.8 · 95% CI -24.0 to 22.7Difference between GSK2894512 0.5 % QD and Vehicle QD at Week 1 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 11.4 · 95% CI -12.0 to 33.9Difference between GSK2894512 1 % BID and Vehicle BID at Week 2 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 30.2 · 95% CI 6.8 to 51.0Difference between GSK2894512 1 % QD and Vehicle QD at Week 2 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: 3.7 · 95% CI -19.4 to 26.6Difference between GSK2894512 0.5 % BID and Vehicle BID at Week 2 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: 17.4 · 95% CI -6.0 to 39.5Difference between GSK2894512 0.5 % QD and Vehicle QD at Week 2 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 16.8 · 95% CI -7.1 to 39.4Difference between GSK2894512 1 % BID and Vehicle BID at Week 4 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 41.9 · 95% CI 19.2 to 61.2Difference between GSK2894512 1 % QD and Vehicle QD at Week 4 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: 8.9 · 95% CI -14.9 to 32.0Difference between GSK2894512 0.5 % BID and Vehicle BID at Week 4 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: 16.3 · 95% CI -7.3 to 38.3Difference between GSK2894512 0.5 % QD and Vehicle QD at Week 4 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 13.4 · 95% CI -11.3 to 36.5Difference between GSK2894512 1 % BID and Vehicle BID at Week 8 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 30.8 · 95% CI 6.1 to 52.8Difference between GSK2894512 1 % QD and Vehicle QD at Week 8 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: 21.9 · 95% CI -3.0 to 44.9Difference between GSK2894512 0.5 % BID and Vehicle BID at Week 8 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: 10.9 · 95% CI -13.5 to 34.7Difference between GSK2894512 0.5 % QD and Vehicle QD at Week 8 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 27.4 · 95% CI 2.5 to 49.9Difference between GSK2894512 1 % BID and Vehicle BID at Week 12 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 16.8 · 95% CI -9.0 to 40.7Difference between GSK2894512 1 % QD and Vehicle QD at Week 12 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: 29.5 · 95% CI 3.7 to 52.3Difference between GSK2894512 0.5 % BID and Vehicle BID at Week 12 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: 5.7 · 95% CI -20.1 to 30.9Difference between GSK2894512 0.5 % QD and Vehicle QD at Week 12 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 9.3 · 95% CI -16.2 to 33.8Difference between GSK2894512 1 % BID and Vehicle BID at Week 14 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 12.6 · 95% CI -13.4 to 37.3Difference between GSK2894512 1 % QD and Vehicle QD at Week 14 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: 27.0 · 95% CI 0.7 to 50.5Difference between GSK2894512 0.5 % BID and Vehicle BID at Week 14 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: 0.4 · 95% CI -25.6 to 25.6Difference between GSK2894512 0.5 % QD and Vehicle QD at Week 14 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 2.6 · 95% CI -22.6 to 27.6Difference between GSK2894512 1 % BID and Vehicle BID at Week 16 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 6.9 · 95% CI -18.7 to 31.7Difference between GSK2894512 1 % QD and Vehicle QD at Week 16 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: 16.8 · 95% CI -9.5 to 41.4Difference between GSK2894512 0.5 % BID and Vehicle BID at Week 16 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: 10.9 · 95% CI -14.9 to 35.8Difference between GSK2894512 0.5 % QD and Vehicle QD at Week 16 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 33.3 · 95% CI -31.9 to 90.6Difference between GSK2894512 1 % BID and Vehicle BID at EW has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: -9.1 · 95% CI -62.4 to 47.8Difference between GSK2894512 1 % QD and Vehicle QD at EW has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: 14.3 · 95% CI -32.2 to 57.9Difference between GSK2894512 0.5 % BID and Vehicle BID at EW has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: 24.2 · 95% CI -40.3 to 80.9Difference between GSK2894512 0.5 % QD and Vehicle QD at EW has been presented.
SecondaryMean Change From Baseline in Total Severity Score (TSS)

A target lesion of at least 3 centimeter square (cm\^2) was selected at Baseline. The severity of the following signs: erythema, induration/papulation, lichenification, oozing/crusting, and scaling was assessed on a 4-point scale ranging from 0 (absent) to 3 (severe), with higher values indicating greater severity of symptoms. TSS (maximum score 15) was calculated based on these signs. Mean change from Baseline in TSS at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit was presented using mean and SD. Baseline value was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Total Severity Score (TSS)
Scores on a scaleGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1; n= 38, 41, 39, 37, 38, 32-1.8 ± 2.04-2.7 ± 2.75-2.1 ± 1.81-1.8 ± 2.02-1.9 ± 2.60-0.9 ± 2.21
Week 2; n= 39, 39, 39, 39, 33, 32-3.6 ± 2.50-4.0 ± 2.42-3.7 ± 2.45-3.3 ± 2.46-3.1 ± 2.73-1.8 ± 2.73
Week 4; n= 38, 39, 38, 39, 30, 32-4.2 ± 2.48-4.5 ± 2.39-5.1 ± 2.58-4.1 ± 2.64-3.3 ± 2.68-3.0 ± 3.03
Week 8; n= 36, 37, 34, 38, 29, 27-4.7 ± 2.37-5.4 ± 2.65-6.1 ± 2.17-5.1 ± 2.34-4.7 ± 2.68-4.3 ± 3.01
Week 12; n= 36, 37, 32, 35, 28, 25-5.8 ± 2.92-5.5 ± 2.64-7.0 ± 2.38-5.5 ± 2.58-4.6 ± 2.64-5.2 ± 2.97
Week 14; n= 34, 35, 31, 33, 27, 25-5.6 ± 2.67-5.1 ± 2.19-5.5 ± 3.22-4.4 ± 3.09-5.0 ± 2.72-5.0 ± 2.88
Week 16; n= 34, 36, 31, 35, 27, 25-5.4 ± 2.98-4.9 ± 2.27-6.0 ± 2.91-5.1 ± 2.65-4.8 ± 2.62-4.9 ± 2.74
EW; n= 3, 4, 7, 3, 11, 11-2.3 ± 4.930.5 ± 5.26-0.4 ± 4.83-2.7 ± 3.51-1.1 ± 3.65-0.1 ± 4.04
SecondaryMean Percent Change From Baseline in TSS

A target lesion of at least 3 cm\^2 was selected at Baseline. The severity of the following signs: erythema, induration/papulation, lichenification, oozing/crusting, and scaling was assessed on a 4-point scale ranging from 0 (absent) to 3 (severe) , with higher values indicating greater severity of symptoms. TSS (maximum score 15) was calculated based on these signs. Mean percent change from Baseline in TSS at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit was presented using mean and SD. Baseline value was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Week 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Reported as:
Mean · Percentage Change
Mean Percent Change From Baseline in TSS
Percentage ChangeGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1; n= 38, 41, 39, 37, 38, 32-23.5 ± 27.99-33.7 ± 31.01-25.8 ± 21.94-22.6 ± 24.78-22.0 ± 27.47-9.8 ± 28.06
Week 2; n= 39, 39, 39, 39, 33, 32-46.7 ± 32.75-52.8 ± 28.45-44.5 ± 26.15-42.4 ± 33.54-35.1 ± 29.29-17.6 ± 40.06
Week 4; n= 38, 39, 38, 39, 30, 32-55.8 ± 31.18-60.1 ± 28.58-60.3 ± 27.68-52.1 ± 33.85-37.4 ± 27.29-33.5 ± 36.16
Week 8; n= 36, 37, 34, 38, 29, 27-61.7 ± 28.14-69.1 ± 27.56-71.0 ± 20.75-65.3 ± 28.31-57.4 ± 31.55-50.0 ± 35.53
Week 12; n= 36, 37, 32, 35, 28, 25-74.3 ± 31.61-73.1 ± 31.69-80.9 ± 18.59-68.6 ± 27.17-56.2 ± 30.53-62.6 ± 30.39
Week 14; n= 34, 35, 31, 33, 27, 25-73.5 ± 30.31-71.1 ± 29.53-63.0 ± 32.96-53.7 ± 35.25-59.7 ± 34.87-60.2 ± 29.97
Week 16; n= 34, 36, 31, 35, 27, 25-69.3 ± 33.20-66.0 ± 30.03-68.8 ± 30.66-63.5 ± 29.78-59.8 ± 33.68-60.3 ± 31.16
EW; n= 3, 4, 7, 3, 11, 11-26.7 ± 64.291.4 ± 82.20-2.9 ± 75.44-40.3 ± 56.57-7.9 ± 41.915.0 ± 59.63
SecondaryMean Change From Baseline in Individual Signs of TSS

The severity of the following signs: erythema, induration/papulation, lichenification, oozing/crusting, and scaling was assessed on a 4-point scale ranging from 0 (absent) to 3 (severe) and TSS (maximum score 15) was calculated based on these signs. Mean change from Baseline in individual signs of TSS was presented using mean and SD. Baseline value was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. If the participant had more than 3 missing days during the week, then the weekly average was not calculated and treated as missing data and excluded from the analysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Individual Signs of TSS
Scores on a scaleGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Erythema; Week 1; n= 38, 41, 39, 37, 38, 32-0.6 ± 0.55-0.8 ± 0.88-0.4 ± 0.63-0.4 ± 0.55-0.4 ± 0.76-0.2 ± 0.66
Erythema; Week 2; n= 39, 39, 39, 39, 33, 32-1.1 ± 0.70-1.1 ± 0.84-0.8 ± 0.76-0.7 ± 0.75-0.6 ± 0.78-0.3 ± 0.93
Erythema; Week 4; n= 38, 39, 38, 39, 30, 32-1.1 ± 0.69-1.3 ± 0.75-1.2 ± 0.79-0.9 ± 0.79-0.8 ± 0.73-0.6 ± 0.87
Erythema; Week 8; n= 36, 37, 34, 38, 29, 27-1.3 ± 0.70-1.5 ± 0.77-1.4 ± 0.61-1.2 ± 0.73-1.2 ± 0.85-0.9 ± 1.01
Erythema; Week 12; n= 36, 37, 32, 35, 28, 25-1.5 ± 0.84-1.5 ± 0.80-1.7 ± 0.69-1.3 ± 0.84-1.1 ± 0.77-1.0 ± 0.89
Erythema; Week 14; n= 34, 35, 31, 33, 27, 25-1.5 ± 0.83-1.4 ± 0.77-1.3 ± 0.97-1.0 ± 0.75-1.2 ± 0.74-1.0 ± 0.79
Erythema; Week 16; n= 34, 36 , 31, 35, 27, 25-1.5 ± 0.83-1.3 ± 0.82-1.4 ± 0.92-1.1 ± 0.77-1.1 ± 0.87-1.0 ± 0.68
Erythema; EW; n= 3, 4, 7, 3, 11, 11-0.7 ± 1.15-0.3 ± 0.96-0.4 ± 0.98-1.0 ± 1.00-0.4 ± 1.12-0.1 ± 1.38
Induration/Papulation;Week 1; n=38,41,39,37,38,32-0.3 ± 0.48-0.6 ± 0.77-0.5 ± 0.68-0.4 ± 0.60-0.3 ± 0.65-0.1 ± 0.55
Induration/Papulation;Week 2;n= 39,39,39,39,33,32-0.8 ± 0.73-1.0 ± 0.87-0.8 ± 0.84-0.8 ± 0.73-0.6 ± 0.87-0.4 ± 0.87
Induration/Papulation;Week 4;n= 38,39,38,39,30,32-1.0 ± 0.82-1.2 ± 0.86-1.1 ± 0.78-0.9 ± 0.83-0.7 ± 0.75-0.7 ± 0.79
Induration/Papulation;Week 8;n= 36,37,34,38,29,27-1.1 ± 0.65-1.2 ± 1.00-1.4 ± 0.66-1.2 ± 0.69-1.0 ± 0.76-0.9 ± 0.75
Induration/Papulation;Week 12;n=36,37,32,35,28,25-1.4 ± 0.87-1.4 ± 0.86-1.6 ± 0.72-1.2 ± 0.73-0.8 ± 0.79-1.1 ± 0.86
Induration/Papulation;Week 14;n=34,35,31,33,27,25-1.3 ± 0.86-1.3 ± 0.64-1.3 ± 0.73-0.9 ± 0.83-0.9 ± 0.75-1.1 ± 0.83
Induration/Papulation;Week 16;n=34,36,31,35,27,25-1.2 ± 0.82-1.2 ± 0.74-1.4 ± 0.75-1.2 ± 0.82-0.8 ± 0.68-1.1 ± 0.91
Induration/Papulation; EW; n= 3,4,7,3,11,11-0.3 ± 1.530.0 ± 0.82-0.1 ± 1.350.0 ± 1.00-0.3 ± 1.190.1 ± 1.38
Lichenification; Week 1;n=38,41,39,37,38,32-0.3 ± 0.63-0.5 ± 0.81-0.4 ± 0.60-0.4 ± 0.54-0.4 ± 0.63-0.2 ± 0.42
Lichenification; Week 2;n=39,39,39,39,33,32-0.6 ± 0.81-0.8 ± 0.78-0.7 ± 0.66-0.7 ± 0.73-0.7 ± 0.78-0.4 ± 0.76
Lichenification; Week 4;n=38,39,38,39,30,32-0.8 ± 0.81-0.9 ± 0.70-1.1 ± 0.73-0.9 ± 0.84-0.6 ± 0.89-0.6 ± 0.88
Lichenification; Week 8;n=36,37,34,38,29,27-0.9 ± 0.83-1.1 ± 0.80-1.2 ± 0.67-1.1 ± 0.74-0.9 ± 0.65-1.0 ± 0.76
Lichenification; Week 12;n=36,37,32,35,28,25-1.2 ± 0.91-1.1 ± 0.75-1.5 ± 0.57-1.2 ± 0.75-1.0 ± 0.67-1.3 ± 0.74
Lichenification; Week 14;n=34,35,31,33,27,25-1.2 ± 0.84-1.0 ± 0.71-1.2 ± 0.83-1.1 ± 0.70-1.0 ± 0.85-1.2 ± 0.82
Lichenification; Week 16;n=34,36,31,35,27,25-1.1 ± 0.98-1.0 ± 0.70-1.3 ± 0.73-1.1 ± 0.72-1.0 ± 0.76-1.2 ± 0.65
Lichenification; EW;n= 3,4,7,3,11,11-0.7 ± 1.150.0 ± 0.82-0.4 ± 0.98-1.0 ± 1.00-0.4 ± 0.81-0.2 ± 0.98
Oozing/crusting; Week 1;n=38,41,39,37,38,32-0.2 ± 0.47-0.4 ± 0.62-0.4 ± 0.63-0.3 ± 0.47-0.3 ± 0.91-0.2 ± 0.68
Oozing/crusting; Week 2;n=39,39,39,39,33,32-0.5 ± 0.60-0.4 ± 0.55-0.7 ± 0.79-0.4 ± 0.55-0.5 ± 0.75-0.4 ± 0.66
Oozing/crusting; Week 4;n=38,39,38,39,30,32-0.6 ± 0.65-0.5 ± 0.64-0.8 ± 0.86-0.6 ± 0.67-0.6 ± 0.82-0.5 ± 0.80
Oozing/crusting; Week 8;n=36,37,34,38,29,27-0.6 ± 0.64-0.6 ± 0.75-1.0 ± 0.90-0.7 ± 0.65-0.6 ± 0.78-0.7 ± 0.82
Oozing/crusting; Week 12;n=36,37,32,35,28,25-0.6 ± 0.60-0.6 ± 0.72-1.1 ± 0.93-0.7 ± 0.66-0.7 ± 0.81-0.8 ± 0.94
Oozing/crusting; Week 14;n=34,35,31,33,27,25-0.6 ± 0.65-0.5 ± 0.78-0.8 ± 1.00-0.5 ± 0.94-0.8 ± 0.79-0.9 ± 0.83
Oozing/crusting; Week 16;n=34,36,31,35,27,25-0.6 ± 0.61-0.6 ± 0.77-1.0 ± 1.03-0.7 ± 0.62-0.8 ± 0.75-0.8 ± 0.87
Oozing/crusting; EW;n=3,4,7,3,11,11-0.3 ± 0.580.8 ± 1.500.6 ± 1.400.0 ± 0.000.0 ± 0.770.1 ± 0.70
Scaling; Week 1;n=38,41,39,37,38,32-0.3 ± 0.85-0.4 ± 0.70-0.4 ± 0.68-0.3 ± 0.78-0.4 ± 0.72-0.2 ± 0.63
Scaling; Week 2;n= 39,39,39,39,33,32-0.6 ± 0.82-0.7 ± 0.68-0.6 ± 0.67-0.6 ± 0.71-0.6 ± 0.78-0.3 ± 0.63
Scaling; Week 4;n=38,39,38,39,30,32-0.8 ± 0.78-0.7 ± 0.69-0.8 ± 0.75-0.8 ± 0.81-0.7 ± 0.71-0.6 ± 0.87
Scaling; Week 8;n=36,37,34,38,29,27-0.8 ± 0.79-0.9 ± 0.66-1.1 ± 0.71-0.9 ± 0.71-1.0 ± 0.76-0.8 ± 0.88
Scaling; Week 12;n=36,37,32,35,28,25-1.1 ± 0.83-0.9 ± 0.70-1.2 ± 0.72-1.0 ± 0.80-1.0 ± 0.67-0.9 ± 0.91
Scaling; Week 14;n=34,35,31,33,27,25-1.0 ± 0.85-0.9 ± 0.73-1.0 ± 0.80-0.8 ± 0.87-1.0 ± 0.81-0.9 ± 0.88
Scaling; Week 16;n=34,36,31,35,27,25-1.0 ± 0.90-0.8 ± 0.75-1.0 ± 0.68-0.9 ± 0.74-1.1 ± 0.70-0.8 ± 0.80
Scaling; EW;n=3,4,7,3,11,11-0.3 ± 0.580.0 ± 1.410.0 ± 0.82-0.7 ± 0.58-0.1 ± 1.040.0 ± 0.89
SecondaryMean Percent Change From Baseline in Individual Signs of TSS

The severity of the following signs: erythema, induration/papulation, lichenification, oozing/crusting, and scaling was assessed on a 4-point scale ranging from 0 (absent) to 3 (severe) and TSS (maximum score 15) was calculated based on these signs. Mean percent change from Baseline in individual signs of TSS was presented using mean and SD. Baseline value was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. NA indicates that data were not available. If the participant had more than 3 missing days during the week, then the weekly average was not calculated and treated as missing data and excluded from the analysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Week 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Reported as:
Mean · Percentage Change
Mean Percent Change From Baseline in Individual Signs of TSS
Percentage ChangeGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Erythema; Week 1; n= 38, 41, 39, 36, 38, 30-25.9 ± 26.76-35.4 ± 37.86-17.1 ± 28.74-19.9 ± 27.26-19.3 ± 34.12-8.9 ± 37.07
Erythema; Week 2; n= 39, 39, 39, 38, 33, 30-49.6 ± 34.30-49.1 ± 35.86-35.5 ± 33.15-36.0 ± 36.46-26.3 ± 39.75-12.8 ± 56.34
Erythema; Week 4; n= 38, 39, 38, 38, 30, 30-51.3 ± 32.74-59.0 ± 32.86-55.7 ± 34.28-45.6 ± 38.10-33.3 ± 37.14-30.6 ± 42.23
Erythema; Week 8; n= 36, 37, 34, 37, 29, 25-58.8 ± 31.24-69.8 ± 33.06-65.7 ± 26.89-58.6 ± 35.05-55.2 ± 40.36-44.0 ± 48.80
Erythema; Week 12; n= 36, 37, 32, 34, 28, 23-69.9 ± 36.69-69.4 ± 37.37-77.1 ± 25.66-66.7 ± 34.33-51.2 ± 36.55-52.2 ± 38.70
Erythema; Week 14; n= 34, 35, 31, 32, 27, 23-70.6 ± 36.71-66.2 ± 37.37-55.9 ± 46.66-49.5 ± 34.26-56.2 ± 35.55-48.6 ± 34.05
Erythema; Week 16; n= 34, 36 , 31, 34, 27, 23-67.2 ± 36.58-59.7 ± 39.11-60.2 ± 44.03-58.8 ± 36.29-50.6 ± 40.95-50.0 ± 30.57
Erythema; EW; n= 3, 4, 7, 3, 11, 11-33.3 ± 57.74-8.3 ± 44.10-21.4 ± 48.80-50.0 ± 50.00-10.6 ± 42.9918.2 ± 87.39
Induration/Papulation;Week 1; n=38,40,37,37,38,32-18.0 ± 26.67-28.3 ± 33.16-21.6 ± 26.02-18.0 ± 25.27-12.7 ± 41.27-3.1 ± 35.78
Induration/Papulation;Week 2;n= 39,38,37,39,33,32-43.2 ± 40.05-46.9 ± 38.91-41.0 ± 40.37-40.6 ± 43.05-22.7 ± 47.47-14.6 ± 55.48
Induration/Papulation;Week 4;n= 38,38,36,39,30,32-49.1 ± 45.84-61.0 ± 38.22-56.5 ± 32.68-43.6 ± 51.24-31.1 ± 32.38-31.8 ± 43.04
Induration/Papulation;Week 8;n= 36,36,33,38,29,27-57.9 ± 35.07-58.8 ± 43.37-70.7 ± 27.96-65.8 ± 36.55-54.0 ± 46.64-44.4 ± 43.85
Induration/Papulation;Week 12;n=36,36,31,35,28,25-72.2 ± 46.97-68.5 ± 43.60-79.6 ± 26.77-65.2 ± 34.39-41.7 ± 47.90-54.7 ± 40.69
Induration/Papulation;Week 14;n=34,34,30,33,27,25-65.7 ± 44.18-73.5 ± 31.55-63.9 ± 32.48-46.5 ± 39.69-50.0 ± 48.48-56.0 ± 39.35
Induration/Papulation;Week 16;n=34,35,30,35,27,25-65.7 ± 42.43-62.4 ± 38.84-67.8 ± 35.81-61.0 ± 38.97-51.2 ± 43.10-52.0 ± 49.14
Induration/Papulation; EW; n= 3,4,6,3,11,110.0 ± 100.00-12.5 ± 62.92-16.7 ± 68.310.0 ± 100.00-4.5 ± 56.8127.3 ± 103.35
Lichenification; Week 1;n=34,37,38,37,37,32-22.1 ± 39.51-30.6 ± 40.73-24.6 ± 39.85-16.7 ± 33.10-19.8 ± 29.88-13.5 ± 28.54
Lichenification; Week 2;n=35,36,38,39,32,32-38.1 ± 45.83-46.3 ± 42.56-36.8 ± 37.60-38.5 ± 41.56-39.1 ± 39.85-19.3 ± 46.97
Lichenification; Week 4;n=34,36,37,39,29,32-47.1 ± 48.80-51.9 ± 36.47-56.3 ± 37.34-45.3 ± 40.64-32.2 ± 46.91-23.4 ± 48.61
Lichenification; Week 8;n=33,35,33,38,28,27-53.5 ± 47.10-62.9 ± 38.58-62.1 ± 32.62-60.1 ± 39.24-53.0 ± 36.59-49.4 ± 37.12
Lichenification; Week 12;n=33,35,31,35,27,25-71.7 ± 41.56-69.0 ± 36.86-78.5 ± 23.25-64.8 ± 37.44-57.4 ± 36.50-67.3 ± 35.84
Lichenification; Week 14;n=31,33,30,33,26,25-73.7 ± 38.19-62.6 ± 43.71-59.4 ± 43.92-56.6 ± 36.07-54.5 ± 40.15-60.7 ± 36.92
Lichenification; Week 16;n=31,34,30,35,26,25-65.6 ± 45.12-60.3 ± 43.81-66.1 ± 34.04-60.0 ± 37.31-57.7 ± 39.79-68.7 ± 33.44
Lichenification; EW;n= 2,2,7,3,11,11-50.0 ± 70.71-25.0 ± 106.07-21.4 ± 69.86-50.0 ± 50.00-16.7 ± 39.44-9.1 ± 62.52
Oozing/crusting; Week 1;n=24,21,26,27,27,22-29.2 ± 52.99-61.9 ± 47.18-40.4 ± 46.95-40.7 ± 48.11-44.4 ± 65.54-20.5 ± 50.38
Oozing/crusting; Week 2;n=24,21,27,28,22,23-64.6 ± 47.73-64.3 ± 42.26-75.9 ± 37.65-51.8 ± 48.08-62.9 ± 44.52-37.0 ± 43.22
Oozing/crusting; Week 4;n= 24,21,27,28,21,24-75.0 ± 44.23-69.0 ± 43.23-79.0 ± 44.96-76.8 ± 41.90-68.3 ± 43.75-45.8 ± 55.00
Oozing/crusting; Week 8;n=23,20,25,27,21,21-82.6 ± 38.76-97.5 ± 11.18-84.7 ± 33.99-85.2 ± 36.20-65.9 ± 43.29-59.5 ± 56.17
Oozing/crusting; Week 12;n=23,20,23,25,21,19-84.8 ± 35.15-87.5 ± 31.93-97.8 ± 10.43-86.0 ± 33.91-74.6 ± 40.35-73.7 ± 71.43
Oozing/crusting; Week 14;n=22,19,23,23,21,19-86.4 ± 35.13-73.7 ± 56.20-84.8 ± 32.14-80.4 ± 39.14-84.9 ± 33.29-76.3 ± 42.06
Oozing/crusting; Week 16;n=22,20,23,25,21,19-79.5 ± 39.82-80.0 ± 41.04-84.8 ± 35.15-84.0 ± 34.52-75.4 ± 41.37-71.1 ± 56.06
Oozing/crusting; EW;n=1,1,4,2,5,5-100.0 ± NA0.0 ± NA-12.5 ± 103.080.0 ± 0.00-20.0 ± 44.72-20.0 ± 44.72
Scaling; Week 1;n=34,36,34,35,36,29-28.4 ± 52.79-36.1 ± 47.22-32.8 ± 47.76-19.5 ± 58.23-24.1 ± 41.87-8.6 ± 42.40
Scaling; Week 2;n= 35,34,34,37,31,30-47.1 ± 45.28-64.7 ± 45.28-53.4 ± 42.60-44.1 ± 51.10-36.6 ± 40.69-12.8 ± 43.04
Scaling; Week 4;n=35,34,34,37,28,30-57.1 ± 45.61-69.1 ± 40.85-68.1 ± 47.38-51.8 ± 52.08-38.1 ± 36.81-33.3 ± 53.07
Scaling; Week 8;n=33,32,30,36,27,25-57.6 ± 50.19-81.3 ± 35.36-81.7 ± 30.75-67.1 ± 43.00-59.3 ± 38.49-50.0 ± 52.04
Scaling; Week 12;n=33,32,29,33,26,23-75.8 ± 41.69-84.4 ± 32.22-82.8 ± 30.69-71.2 ± 48.46-64.7 ± 37.51-54.3 ± 52.03
Scaling; Week 14;n=31,30,28,31,25,23-74.2 ± 40.56-73.3 ± 48.66-70.2 ± 39.11-60.2 ± 63.78-62.0 ± 39.24-52.2 ± 43.90
Scaling; Week 16;n=31,31,28,33,25,23-75.8 ± 48.08-66.1 ± 50.64-72.0 ± 36.87-65.7 ± 44.08-70.7 ± 35.45-51.4 ± 51.23
Scaling; EW;n=2,4,5,3,9,9-50.0 ± 70.710.0 ± 141.42-10.0 ± 74.16-50.0 ± 50.00-5.6 ± 76.830.0 ± 70.71
SecondaryMean Change From Baseline in Body Surface Area (Percent BSA)

The extent of BSA affected by AD is a general indicator of disease severity and the assessment of BSA with AD was performed separately for four body surface regions: the head (h), the upper extremities (u), the trunk (t) and the lower extremities (l), corresponding to 10, 20, 30, and 40 percent of the total body area, respectively. Mean change from Baseline in percent BSA was presented using mean and SD at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit. Baseline was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Reported as:
Mean · Percentage of surface area
Mean Change From Baseline in Body Surface Area (Percent BSA)
Percentage of surface areaGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1; n= 38, 41, 39, 37, 38, 32-2.37 ± 4.774-3.57 ± 5.498-2.44 ± 4.313-1.52 ± 6.078-0.33 ± 6.591-0.25 ± 4.411
Week 2; n= 39, 39, 39, 39, 33, 32-4.99 ± 7.330-7.07 ± 6.639-4.88 ± 5.243-3.78 ± 5.897-2.01 ± 6.484-0.04 ± 4.698
Week 4; n= 38, 39, 38, 39, 30, 32-7.37 ± 6.276-9.76 ± 8.581-7.47 ± 7.567-7.07 ± 6.382-2.93 ± 7.772-2.05 ± 6.517
Week 8; n= 36, 37, 34, 38, 29, 27-9.23 ± 8.425-11.70 ± 9.208-10.89 ± 9.692-8.56 ± 6.217-5.41 ± 7.961-3.33 ± 7.264
Week 12; n= 36, 37, 32, 35, 28, 25-11.19 ± 8.643-11.55 ± 9.690-12.18 ± 9.581-9.81 ± 7.717-6.00 ± 8.424-5.44 ± 8.079
Week 14; n= 34, 35, 31, 33, 27, 25-9.25 ± 7.121-9.85 ± 9.446-11.26 ± 10.262-9.26 ± 7.529-5.60 ± 7.575-5.80 ± 6.987
Week 16; n= 34, 36, 31, 35, 27, 25-8.19 ± 7.826-9.93 ± 8.820-10.92 ± 9.903-9.25 ± 8.399-5.66 ± 7.695-5.53 ± 7.227
EW; n= 3, 4, 7, 3, 11, 11-2.60 ± 4.6134.63 ± 9.5865.36 ± 21.4683.20 ± 14.4683.36 ± 9.4927.50 ± 18.476
SecondaryMean Change From Baseline in IGA Score

The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. IGA is made without reference to previous scores. Score ranges from 0 (clear) to 4 (severe). Higher values represent a severe disease. Mean change from Baseline in IGA score was presented using mean and SD at Week 1, Week 2, Week 4, Week 8, Week 12, Week 14 (follow up 1), Week 16 (follow up 2) and EW visit. Baseline was defined as the latest assessment prior to first dose and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in IGA Score
Scores on a scaleGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1; n= 38, 41, 39, 37, 38, 32-0.5 ± 0.60-0.6 ± 0.67-0.3 ± 0.48-0.4 ± 0.55-0.3 ± 0.58-0.4 ± 0.62
Week 2; n= 39, 39, 39, 39, 33, 32-1.0 ± 0.69-0.9 ± 0.70-0.6 ± 0.67-0.7 ± 0.79-0.7 ± 0.72-0.5 ± 0.72
Week 4; n= 38, 39, 38, 39, 30, 32-1.3 ± 0.86-1.4 ± 0.81-1.1 ± 0.77-1.0 ± 0.81-1.0 ± 0.72-0.7 ± 0.82
Week 8; n= 36, 37, 34, 38, 29, 27-1.4 ± 0.83-1.6 ± 0.82-1.3 ± 0.84-1.4 ± 0.85-1.2 ± 0.60-1.0 ± 0.88
Week 12; n= 36, 37, 32, 35, 28, 25-1.7 ± 0.96-1.6 ± 0.83-1.6 ± 0.76-1.5 ± 0.95-1.3 ± 0.72-1.2 ± 0.78
Week 14; n= 34, 35, 31, 33, 27, 25-1.5 ± 1.08-1.4 ± 0.77-1.5 ± 0.99-1.3 ± 0.92-1.2 ± 0.85-1.2 ± 0.75
Week 16; n= 34, 36, 31, 35, 27, 25-1.2 ± 1.07-1.2 ± 0.74-1.4 ± 0.91-1.3 ± 0.94-1.3 ± 0.90-1.1 ± 0.73
EW; n= 3, 4, 7, 3, 11, 11-1.3 ± 1.530.3 ± 0.50-0.6 ± 0.98-1.0 ± 1.000.1 ± 0.300.0 ± 0.89
SecondaryPercentage of Participants Who Have an IGA Score of Clear or Almost Clear (0 or 1) and a Minimum 2 Grade Improvement in IGA Score From Baseline to Each Study Visit

The IGA is a clinical tool for assessing the current state/severity of a participant's AD. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines. IGA is made without reference to previous scores. The percentage of participants who have an IGA score of clear or almost clear and a minimum 2 grade improvement from Baseline to each study visit in IGA score was presented. The statistical analysis was performed using a repeated measures factorial logistic regression model with covariates for dose, frequency of administration, and study day as well as a dose by frequency interaction term. The analysis was performed on ITT Population which comprised of all randomized participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category title).

Time frame:
Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to week 16)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Have an IGA Score of Clear or Almost Clear (0 or 1) and a Minimum 2 Grade Improvement in IGA Score From Baseline to Each Study Visit
Percentage of participantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1; n= 38,41,39,37,38,32550333
Week 2; n= 39,39,39,39,33,3218181013159
Week 4; n= 38,39,38,39,30,3232382623209
Week 8; n= 36,37,34,38,29,27425438422819
Week 12; n= 36,37,32,35,28,25585150403644
Week 14; n= 34,35,31,33,27,25444352362636
Week 16; n= 34,36,31,35,27,25353639403028
EW; n= 3,4,7,3,11,11330143309
Statistical analysis
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: -7.7 · 95% CI -45.8 to 32.5Difference between GSK2894512 1 % BID and Vehicle BID at Week 1 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 15.4 · 95% CI -25.7 to 52.6Difference between GSK2894512 1 % QD and vehicle QD at Week 1 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: -7.7 · 95% CI -46.0 to 32.6Difference between GSK2894512 0.5 % BID and vehicle BID at Week 1 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: 9.1 · 95% CI -32.2 to 48.8Difference between GSK2894512 0.5 % QD and vehicle QD at Week 1 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: -24.2 · 95% CI -60.8 to 14.8Difference between GSK2894512 1 % BID and vehicle BID at Week 2 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 28.5 · 95% CI -13.7 to 63.0Difference between GSK2894512 1 % QD and vehicle QD at Week 2 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: -33.3 · 95% CI -67.4 to 6.1Difference between GSK2894512 0.5 % BID and vehicle BID at Week 2 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: -0.9 · 95% CI -40.7 to 40.7Difference between GSK2894512 0.5 % QD and vehicle QD at Week 2 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: -15.2 · 95% CI -53.8 to 23.5Difference between GSK2894512 1 % BID and vehicle BID at Week 4 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 43.4 · 95% CI 2.7 to 74.6Difference between GSK2894512 1 % QD and vehicle QD at Week 4 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: -15.2 · 95% CI -53.8 to 23.5Difference between GSK2894512 0.5 % BID and vehicle BID at Week 4 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: 9.1 · 95% CI -35.6 to 51.2Difference between GSK2894512 0.5 % QD and vehicle QD at Week 4 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 18.3 · 95% CI -25.1 to 57.1Difference between GSK2894512 1 % BID and vehicle BID at Week 8 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 47.7 · 95% CI 4.8 to 78.7Difference between GSK2894512 1 % QD and vehicle QD at Week 8 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: -11.7 · 95% CI -51.3 to 30.2Difference between GSK2894512 0.5 % BID and vehicle BID at Week 8 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: 9.1 · 95% CI -35.6 to 51.2Difference between GSK2894512 0.5 % QD and vehicle QD at Week 8 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: 6.4 · 95% CI -35.4 to 48.5Difference between GSK2894512 1 % BID and Vehicle BID at Week 12 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 6.0 · 95% CI -35.8 to 47.1Difference between GSK2894512 1 % QD and Vehicle QD at Week 12 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: -13.6 · 95% CI -54.0 to 31.2Difference between GSK2894512 0.5 % BID and Vehicle BID at Week 12 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: -25.6 · 95% CI -65.3 to 22.4Difference between GSK2894512 0.5 % QD and Vehicle QD at Week 12 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: -1.0 · 95% CI -44.5 to 42.7Difference between GSK2894512 1 % BID and Vehicle BID at Week 14 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 5.6 · 95% CI -37.8 to 47.3Difference between GSK2894512 1 % QD and Vehicle QD at Week 14 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: -5.5 · 95% CI -47.9 to 37.6Difference between GSK2894512 0.5 % BID and Vehicle BID at Week 14 has been presented.
  • GSK2894512 0.5% QD vs Vehicle QD · Difference in percentages: -4.4 · 95% CI -48.3 to 41.5Difference between GSK2894512 0.5 % QD and Vehicle QD at Week 14 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Difference in percentages: -1.0 · 95% CI -44.5 to 42.7Difference between GSK2894512 1 % BID and Vehicle BID at Week 16 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Difference in percentages: 8.3 · 95% CI -35.0 to 49.2Difference between GSK2894512 1 % QD and Vehicle QD at Week 16 has been presented.
  • GSK2894512 0.5% BID vs Vehicle BID · Difference in percentages: -3.3 · 95% CI -46.0 to 42.3Difference between GSK2894512 0.5 % BID and Vehicle BID at Week 16 has been presented.
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function. Treatment emergent AEs (TEAE) is defined as AE occurred on or after study treatment start date and on or before last visit. Number of participants with AEs and serious TEAEs were presented. The analysis was performed on Safety population which comprised of all participants who receive at least one dose of study treatment.

Time frame:
Weeks 1, 2, 4, 8, 12, 14, EW (up to week 14)
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
TEAEs282220231915
Serious TEAEs100000
SecondaryNumber of Participants With Reported Tolerability Score of 0 to 4 Over Time

Participants were asked to use a 5-point tolerability scale from 0 (none) to 4 (severe) to assess the presence and degree of burning/stinging and itching at the application sites that has generally been experienced following application of the study treatment. The score represented an 'average' across all application sites. A score of 3 or 4 was reported as an AE. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Week 1, 2, 4, 8, 12, 14, EW (up to Week 14)
Reported as:
Number · Participants
Number of Participants With Reported Tolerability Score of 0 to 4 Over Time
ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1; none; n= 38,40,39,37,38,33192525211522
Week 1; slight; n= 38,40,39,37,38,336105695
Week 1; mild; n= 38,40,39,37,38,33932863
Week 1; Moderate; n= 38,40,39,37,38,33226272
Week 1; severe; n= 38,40,39,37,38,33201011
Week 2; none; n= 39,37,39,39,33,32262733201618
Week 2; slight;n= 39,37,39,39,33,325511165
Week 2; mild; n= 39,37,39,39,33,32344485
Week 2; moderate; n= 39,37,39,39,33,32401322
Week 2; severe; n= 39,37,39,39,33,32110112
Week 4; none; n= 38, 39, 38,39,29,32262627271521
Week 4; slight; n= 38, 39, 38,39,29,32785982
Week 4; mild; n= 38, 39, 38,39,29,32346245
Week 4; moderate; n= 38, 39, 38,39,29,32210123
Week 4; severe; n= 38, 39, 38,39,29,32000001
Week 8; none; n= 36, 37, 34, 38, 29, 28252823291917
Week 8; slight; n= 36, 37, 34, 38, 29, 28668755
Week 8; mild; n= 36, 37, 34, 38, 29, 28322233
Week 8; moderate; n= 36, 37, 34, 38, 29, 28111013
Week 8; severe; n= 36, 37, 34, 38, 29, 28100010
Week 12; none; n= 36, 37, 32, 35, 28, 28242726271623
Week 12; slight; n= 36, 37, 32, 35, 28, 28683683
Week 12; mild; n= 36, 37, 32, 35, 28, 28513230
Week 12; moderate; n= 36, 37, 32, 35, 28, 28100010
Week 12; severe; n= 36, 37, 32, 35, 28, 28010002
Week 14; none; n= 34,35,32,33,31,29262927262222
Week 14; slight; n= 34,35,32,33,31,29454544
Week 14; mild; n= 34,35,32,33,31,29300222
Week 14; moderate; n= 34,35,32,33,31,29111021
Week 14; severe; n= 34,35,32,33,31,29000010
EW; none; n= 3,4,7,3,11,11214237
EW; slight; n= 3,4,7,3,11,11010040
EW; mild; n= 3,4,7,3,11,11110001
EW; moderate; n= 3,4,7,3,11,11012112
EW; severe; n= 3,4,7,3,11,11001031
SecondaryChange From Baseline in Albumin and Total Protein

Blood samples were collected to evaluate change from Baseline in albumin and total protein values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

Time frame:
Week 1, 2, 4, 8, 12, 14, EW (up to week 14)
Reported as:
Mean · Gram per Liter (G/L)
Change From Baseline in Albumin and Total Protein
Gram per Liter (G/L)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Albumin; Week 2; n=38,39,38,39,33,32-1.2 ± 2.96-1.3 ± 1.89-2.2 ± 2.96-1.4 ± 2.02-1.2 ± 3.91-1.2 ± 2.17
Albumin; Week 4; n=38,39,38,38,30,32-1.1 ± 2.87-0.6 ± 2.17-1.9 ± 2.49-1.3 ± 2.74-1.2 ± 2.46-0.7 ± 2.74
Albumin; Week 8; n= 35,37,34,38,29,28-1.7 ± 2.47-1.0 ± 1.86-1.9 ± 2.38-1.1 ± 2.29-1.4 ± 2.54-1.4 ± 3.14
Albumin; Week 12; n= 36,37,32,35,28,28-1.1 ± 2.48-1.2 ± 2.65-2.2 ± 2.35-1.7 ± 2.47-1.6 ± 2.79-0.9 ± 2.09
Albumin; Week 14; n= 33,35,32,34,31,29-1.6 ± 2.36-1.5 ± 2.41-2.0 ± 2.48-1.6 ± 3.04-2.0 ± 2.70-0.9 ± 2.21
Albumin; EW;n = 3,3,7,3,11,11-1.3 ± 4.04-3.3 ± 2.52-3.0 ± 1.29-0.7 ± 0.58-0.7 ± 2.87-2.5 ± 2.84
Total protein; Week 2; n= 38,39,38,39,33,32-1.5 ± 4.49-2.2 ± 2.84-2.3 ± 4.48-2.0 ± 3.34-1.9 ± 6.66-1.6 ± 3.31
Total protein; Week 4; n= 38,39,38,38,30,32-1.9 ± 4.32-1.1 ± 3.49-2.4 ± 4.43-1.7 ± 5.12-2.3 ± 3.86-1.1 ± 4.62
Total protein; Week 8; n= 35,37,34,38,29,28-2.8 ± 3.91-2.1 ± 3.02-2.8 ± 4.46-1.7 ± 3.89-1.7 ± 4.09-1.8 ± 4.82
Total protein; Week 12; n= 36,37,32,35,28,28-2.0 ± 4.16-2.5 ± 4.43-3.8 ± 4.40-2.4 ± 4.07-2.2 ± 5.38-1.0 ± 3.18
Total protein; Week 14; n= 33,35,32,34,31,29-3.0 ± 3.80-2.4 ± 3.23-3.3 ± 4.07-2.0 ± 4.75-2.3 ± 4.26-1.3 ± 3.84
Total protein; EW; n= 3,3,7,3,11,11-2.3 ± 6.43-4.0 ± 2.00-2.0 ± 2.16-1.0 ± 2.00-1.4 ± 3.64-3.0 ± 5.08
SecondaryChange From Baseline in Alkaline Phosphatase (Alk.Phosph.), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Gamma Glutamyl Transferase (GGT)

Blood samples were collected to evaluate change from Baseline in Alk.phosph., ALT, AST and GGT values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

Time frame:
Week 2, 4, 8, 12, 14, EW (up to week 14)
Reported as:
Mean · International unit per liter (IU/L)
Change From Baseline in Alkaline Phosphatase (Alk.Phosph.), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Gamma Glutamyl Transferase (GGT)
International unit per liter (IU/L)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Alk.Phosph.; Week 2; n= 38,39,38,39,33,323.7 ± 14.58-1.7 ± 12.243.7 ± 21.04-2.3 ± 13.49-2.3 ± 15.32-2.0 ± 8.70
Alk.Phosph.; Week 4; n= 38,39,38,38,30,322.1 ± 15.59-0.4 ± 12.171.7 ± 15.22-2.7 ± 12.36-3.8 ± 16.24-3.9 ± 9.79
Alk.Phosph.; Week 8; n= 35,37,34,38,29,282.0 ± 12.40-0.7 ± 9.39-1.2 ± 12.85-4.8 ± 18.15-1.6 ± 19.08-5.7 ± 12.03
Alk.Phosph.; Week 12; n= 36,37,32,35,28,283.1 ± 15.36-0.4 ± 10.14-5.1 ± 18.47-6.3 ± 17.29-8.1 ± 21.60-7.8 ± 15.34
Alk. Phosph.; Week 14; n= 33,35,32,34,31,29-1.4 ± 13.46-3.0 ± 17.56-7.2 ± 19.31-7.2 ± 20.07-6.5 ± 24.86-8.3 ± 14.83
Alk.Phosph.; EW; n= 3,3,7,3,11,11-2.3 ± 27.745.3 ± 12.508.0 ± 18.130.3 ± 9.870.9 ± 6.74-0.5 ± 7.39
ALT; Week 2; n= 38,39,38,39,33,323.6 ± 21.02-1.8 ± 3.927.7 ± 28.011.5 ± 12.520.2 ± 7.210.2 ± 6.06
ALT; Week 4; n= 38,39,38,38,30,32-0.8 ± 9.20-1.1 ± 5.232.7 ± 8.071.7 ± 9.280.3 ± 7.630.6 ± 4.55
ALT; Week 8; n= 35,37,34,38,29,284.9 ± 30.93-1.4 ± 7.001.2 ± 6.77-1.5 ± 3.98-2.0 ± 6.060.3 ± 5.16
ALT; Week 12; n= 36,37,32,35,28,28-0.3 ± 12.51-3.1 ± 4.78-1.4 ± 4.13-0.6 ± 4.640.8 ± 7.97-0.2 ± 5.58
ALT; Week 14; n= 33,35,32,34,31,293.3 ± 24.10-3.2 ± 5.47-0.9 ± 4.51-1.0 ± 3.93-0.5 ± 5.58-0.8 ± 3.15
ALT; EW; n= 3,3,7,3,11,1113.0 ± 37.64-3.7 ± 16.6211.3 ± 36.602.0 ± 6.56-1.7 ± 4.733.3 ± 7.70
AST; Week 2; n= 38,39,38,39,33,321.6 ± 9.36-1.3 ± 2.983.1 ± 13.840.2 ± 4.99-0.8 ± 4.990.5 ± 3.54
AST; Week 4; n=38,39,38,38,30,32-0.4 ± 5.24-1.1 ± 4.181.0 ± 6.371.1 ± 6.810.0 ± 5.680.5 ± 4.17
AST; Week 8; n= 35,37,34,38,29,2818.4 ± 97.92-0.9 ± 5.060.2 ± 4.80-1.1 ± 4.56-1.9 ± 6.05-0.1 ± 5.80
AST; Week 12; n=36,37,32,35,28,280.1 ± 8.54-1.2 ± 4.67-1.3 ± 5.12-0.7 ± 4.900.9 ± 6.880.2 ± 5.20
AST; Week 14; n= 33,35,32,34,31,294.4 ± 28.19-2.2 ± 4.89-1.3 ± 3.92-1.1 ± 3.480.5 ± 8.120.0 ± 4.49
AST; EW; n= 3,3,7,3,11,114.7 ± 8.621.7 ± 14.574.0 ± 12.833.0 ± 1.73-0.8 ± 2.143.1 ± 6.30
GGT; Week 2; n= 38,39,38,39,33,32-0.3 ± 6.36-1.3 ± 4.614.0 ± 13.820.7 ± 3.49-0.9 ± 8.04-2.9 ± 9.86
GGT; Week 4; n= 38,39,38,38,30,32-2.1 ± 9.47-0.8 ± 4.011.3 ± 6.380.9 ± 4.870.1 ± 10.95-1.0 ± 4.79
GGT; Week 8; n= 35,37,34,38,29,28-2.0 ± 14.19-1.2 ± 4.801.6 ± 10.32-0.5 ± 6.96-0.2 ± 11.680.4 ± 5.73
GGT; Week 12; n= 36,37,32,35,28,28-1.8 ± 14.77-1.6 ± 4.050.8 ± 8.381.1 ± 4.521.7 ± 11.651.9 ± 7.12
GGT; Week 14; n= 33,35,32,34,31,29-2.2 ± 15.76-1.0 ± 3.430.7 ± 4.931.0 ± 3.630.1 ± 8.19-0.3 ± 3.07
GGT; EW; n= 3,3,7,3,11,115.7 ± 31.01-8.0 ± 16.523.7 ± 9.48-0.7 ± 7.23-1.9 ± 8.19-4.8 ± 17.11
SecondaryChange From Baseline in Direct and Total Bilirubin, Creatinine and Urate

Blood samples were collected to evaluate change from Baseline in direct and total bilirubin, creatinine and urate values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

Time frame:
Week 2, 4, 8, 12, 14, EW (up to week 14)
Reported as:
Mean · Micromoles per liter (µmol/L)
Change From Baseline in Direct and Total Bilirubin, Creatinine and Urate
Micromoles per liter (µmol/L)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Direct bilirubin; Week 2; n= 38,39,38,39,33,32-0.1 ± 0.98-0.3 ± 1.08-0.5 ± 1.18-0.1 ± 1.070.0 ± 1.66-0.3 ± 1.15
Direct bilirubin; Week 4; n= 38,39,38,38,30,32-0.1 ± 1.18-0.3 ± 0.82-0.5 ± 1.18-0.2 ± 1.020.1 ± 1.23-0.4 ± 0.94
Direct bilirubin; Week 8; n= 35,37,34, 38,29,280.1 ± 1.41-0.2 ± 0.99-0.4 ± 1.08-0.2 ± 1.260.1 ± 1.36-0.5 ± 1.17
Direct bilirubin; Week 12; n= 36,37,32,35,28,280.3 ± 1.190.0 ± 1.15-0.4 ± 0.94-0.2 ± 1.170.0 ± 1.33-0.1 ± 1.21
Direct bilirubin; Week 14; n= 33,35,32,34,31,29-0.1 ± 1.17-0.2 ± 1.320.1 ± 1.19-0.2 ± 1.070.0 ± 1.26-0.3 ± 1.58
Direct bilirubin; EW; n= 3,3,7,3,11,110.0 ± 2.00-0.7 ± 1.15-0.6 ± 0.98-0.7 ± 1.15-0.5 ± 1.810.0 ± 1.26
Total bilirubin; Week 2; n=38,39,38,39,33,32-1.1 ± 3.21-0.8 ± 3.23-2.2 ± 3.37-0.6 ± 2.64-0.4 ± 5.49-0.1 ± 2.80
Total bilirubin; Week 4; n= 38,39,38,38,30,32-1.2 ± 3.18-0.8 ± 2.54-1.5 ± 3.11-1.4 ± 3.150.3 ± 4.270.0 ± 2.16
Total bilirubin; Week 8; n= 35,37,34, 38,29,280.0 ± 4.97-0.3 ± 2.93-1.8 ± 3.24-0.8 ± 4.50-0.1 ± 5.06-1.1 ± 2.14
Total bilirubin; Weel 12; n= 36,37,32,35,28,280.5 ± 4.150.1 ± 2.26-1.9 ± 2.56-0.9 ± 3.300.6 ± 4.42-0.1 ± 3.17
Total bilirubin; Week 14; n= 33,35,32,34,31,29-0.1 ± 2.81-0.4 ± 3.900.0 ± 4.10-0.6 ± 3.430.1 ± 3.92-0.4 ± 4.19
Total bilirubin; EW; n = 3,3,7,3,11,11-1.3 ± 5.77-2.0 ± 2.00-0.9 ± 3.44-0.7 ± 1.150.5 ± 4.82-0.4 ± 4.27
Creatinine; Week 2; n= 38,39,38,39,33,32-3.00 ± 10.771-3.65 ± 6.186-3.46 ± 7.165-0.84 ± 7.294-1.56 ± 10.4610.11 ± 8.059
Creatinine; Week 4; n= 38,39,38,38,30,32-0.04 ± 11.471-3.30 ± 6.974-1.14 ± 7.8970.51 ± 8.990-1.19 ± 10.9453.70 ± 14.019
Creatinine; Week 8; n= 35,37,34, 38,29,28-2.03 ± 12.571-1.70 ± 8.249-0.29 ± 8.357-0.04 ± 8.114-0.58 ± 11.799-0.51 ± 7.530
Creatinine; Week 12; n= 36,37,32,35,28,28-1.84 ± 11.918-1.41 ± 9.5730.16 ± 5.8861.03 ± 7.618-0.70 ± 10.7891.58 ± 6.241
Creatinine; Week 14; n= 33,35,32,34,31,292.04 ± 10.306-1.48 ± 9.9862.77 ± 7.3513.17 ± 7.990-0.05 ± 7.8591.52 ± 5.860
Creatinine; EW; n=3,3,7,3,11,111.20 ± 2.651-5.33 ± 2.650-8.19 ± 9.071-4.13 ± 8.251-1.35 ± 8.3860.09 ± 11.172
Urate; Week 2; n= 38,39,38,39,33,32-26.1 ± 74.09-7.9 ± 41.56-14.5 ± 43.917.9 ± 49.960.0 ± 50.192.5 ± 38.44
Urate; Week 4; n=38,39,38,38,30,32-18.7 ± 58.92-8.7 ± 39.21-2.9 ± 52.963.9 ± 59.84-2.7 ± 62.6924.1 ± 62.21
Urate; Week 8; n=35,37,34, 38,29,28-20.0 ± 60.44-0.5 ± 52.54-7.9 ± 51.63-5.5 ± 59.7612.8 ± 44.0712.9 ± 59.25
Urate; Week 12; n=36,37,32,35,28,28-20.8 ± 70.48-5.1 ± 93.20-14.7 ± 46.972.6 ± 60.896.8 ± 51.435.0 ± 46.79
Urate; Week 14; n=33,35,32,34,31,29-10.9 ± 58.44-5.4 ± 46.863.8 ± 48.6415.9 ± 61.505.2 ± 56.3217.2 ± 43.33
Urate; EW; n=3,3,7,3,11,11-6.7 ± 20.82-16.7 ± 15.28-22.9 ± 39.46-16.7 ± 85.050.9 ± 42.308.2 ± 43.55
SecondaryChange From Baseline in Calcium, Chloride, Carbon Dioxide (CO2), Glucose, Potassium, Sodium, Blood Urea Nitrogen (BUN)

Blood samples were collected to evaluate change from Baseline in calcium, chloride, CO2, glucose, potassium, sodium and BUN values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

Time frame:
Week 2, 4, 8, 12, 14, EW (up to week 14)
Reported as:
Mean · Millimoles per liter (mmol/L)
Change From Baseline in Calcium, Chloride, Carbon Dioxide (CO2), Glucose, Potassium, Sodium, Blood Urea Nitrogen (BUN)
Millimoles per liter (mmol/L)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Calcium; Week 2; n= 38,39,38,39,33,32-0.042 ± 0.0941-0.037 ± 0.0918-0.067 ± 0.0970-0.022 ± 0.0822-0.024 ± 0.1346-0.027 ± 0.0758
Calcium; Week 4; n= 38,39,38,38,30,32-0.037 ± 0.1076-0.014 ± 0.0899-0.050 ± 0.0873-0.028 ± 0.0840-0.031 ± 0.0952-0.031 ± 0.0900
Calcium; Week 8; n=35,37,34,38,29,28-0.053 ± 0.0939-0.024 ± 0.0973-0.063 ± 0.0800-0.025 ± 0.0754-0.035 ± 0.0989-0.038 ± 0.0788
Calcium; Week 12; n=36,37,32,35,28,28-0.022 ± 0.0928-0.028 ± 0.0861-0.061 ± 0.0934-0.029 ± 0.0911-0.026 ± 0.1112-0.004 ± 0.0596
Calcium; Week 14; n=33,35,32,34,31,29-0.022 ± 0.0793-0.019 ± 0.0787-0.037 ± 0.0964-0.019 ± 0.0868-0.028 ± 0.0897-0.024 ± 0.0668
Calcium; EW; n= 3,3,7,3,11,11-0.073 ± 0.1102-0.053 ± 0.1405-0.003 ± 0.1122-0.047 ± 0.0503-0.025 ± 0.1092-0.038 ± 0.0914
Chloride; Week 2; n= 38,39,38,39,33,320.5 ± 2.680.9 ± 2.320.2 ± 2.680.6 ± 2.22-0.5 ± 2.490.4 ± 2.27
Chloride; Week 4; n=38,39,38,38,30,320.5 ± 2.540.1 ± 2.310.5 ± 2.050.3 ± 2.26-0.4 ± 2.010.5 ± 2.38
Chloride; Week 8; n= 35,37,34,38,29,281.0 ± 2.320.5 ± 1.990.5 ± 2.27-0.3 ± 2.45-0.4 ± 2.210.5 ± 2.86
Chloride; Week 12; n= 36,37,32,35,28,280.1 ± 2.570.7 ± 2.310.3 ± 1.850.5 ± 2.44-0.4 ± 1.83-0.1 ± 2.76
Chloride; Week 14; n=33,35,32,34,31,290.9 ± 2.340.4 ± 1.820.1 ± 2.87-0.1 ± 2.40-0.3 ± 2.320.6 ± 2.64
Chloride; EW; n= 3,3,7,3,11,11-1.0 ± 1.001.3 ± 1.530.3 ± 1.981.0 ± 2.000.1 ± 1.700.6 ± 2.66
CO2; Week 2; n= 38,39,38,39,33,32-1.8 ± 2.04-0.8 ± 2.52-1.2 ± 2.30-0.4 ± 2.47-0.9 ± 2.39-1.0 ± 2.15
CO2; Week 4; n= 38,39,38,38,30,32-1.4 ± 1.98-0.8 ± 3.07-1.3 ± 2.14-0.7 ± 2.22-0.5 ± 2.71-1.0 ± 2.06
CO2; Week 8; n= 35,37,34,38,29,28-1.9 ± 2.34-1.1 ± 3.35-1.1 ± 2.21-0.7 ± 2.60-0.8 ± 2.43-1.8 ± 2.65
CO2; Week 12; n=36,37,32,35,28,28-1.1 ± 2.12-1.0 ± 3.20-1.1 ± 2.45-0.7 ± 2.10-0.5 ± 2.49-1.1 ± 2.07
CO2; Week 14; n=33,35,32,34,31,29-1.1 ± 2.23-0.8 ± 3.09-1.3 ± 2.59-0.6 ± 3.13-0.9 ± 2.29-1.3 ± 1.86
CO2; EW; n=3,3,7,3,11,110.0 ± 1.00-0.3 ± 2.08-1.9 ± 3.180.3 ± 1.530.0 ± 2.19-0.4 ± 1.80
Glucose; Week 2; n=38,39,38,39,33,320.55 ± 1.7100.65 ± 1.3840.13 ± 1.0840.37 ± 1.4310.46 ± 0.687-0.10 ± 3.059
Glucose; Week 4; n= 38,39,38,38,30,320.53 ± 1.3340.25 ± 1.1010.02 ± 1.0890.64 ± 1.2090.38 ± 1.154-0.00 ± 3.164
Glucose; Week 8; n=35,37,34,38,29,280.40 ± 1.4500.42 ± 1.2530.01 ± 0.9420.51 ± 1.1060.44 ± 1.048-0.34 ± 3.256
Glucose; Week 12; n= 36,37,32,35,28,280.22 ± 1.6640.16 ± 0.9900.01 ± 1.0970.36 ± 1.0770.50 ± 1.028-0.49 ± 3.240
Glucose; Week 14; n=33,35,32,34,31,290.29 ± 1.0910.47 ± 1.275-0.14 ± 1.4650.14 ± 1.4820.12 ± 0.868-0.52 ± 3.871
Glucose; EW; n= 3,3,7,3,11,11-0.30 ± 0.557-0.70 ± 0.8890.67 ± 1.154-0.10 ± 2.0070.32 ± 0.8730.11 ± 0.997
Potassium; Week 2; n= 38,39,38,39,33,32-0.06 ± 0.3180.04 ± 0.3600.04 ± 0.3590.03 ± 0.3810.08 ± 0.3710.03 ± 0.339
Potassium; Week 4; n= 38,39,38,38,30,32-0.02 ± 0.3590.09 ± 0.4460.19 ± 0.7400.01 ± 0.3370.04 ± 0.2540.01 ± 0.428
Potassium; Week 8; n= 35,37,34,38,29,280.05 ± 0.3890.09 ± 0.3030.19 ± 0.7650.03 ± 0.3160.04 ± 0.344-0.06 ± 0.370
Potassium; Week 12; n= 36,37,32,35,28,280.04 ± 0.3710.13 ± 0.335-0.01 ± 0.449-0.01 ± 0.3390.06 ± 0.3980.01 ± 0.403
Potassium; Week 14; n=33,35,32,34,31,290.09 ± 0.3090.13 ± 0.4220.09 ± 0.5700.03 ± 0.3490.14 ± 0.503-0.00 ± 0.348
Potassium; EW; n= 3,3,7,3,11,11-0.20 ± 0.100-0.13 ± 0.2080.10 ± 0.252-0.37 ± 0.058-0.02 ± 0.236-0.00 ± 0.366
Sodium; Week 2; n= 38,39,38,39,33,32-0.5 ± 2.190.1 ± 2.17-0.1 ± 2.33-0.3 ± 2.19-0.4 ± 1.90-0.2 ± 1.60
Sodium; Week 4; n= 38,39,38,38,30,32-0.1 ± 2.16-0.5 ± 1.94-0.2 ± 1.78-0.9 ± 1.83-0.3 ± 2.14-0.1 ± 1.65
Sodium; Week 8; n=35,37,34,38,29,28-0.3 ± 2.19-0.2 ± 2.75-0.2 ± 2.21-0.7 ± 1.94-0.6 ± 1.84-0.0 ± 2.50
Sodium; Week 12; n=36,37,32,35,28,28-0.4 ± 2.11-0.4 ± 2.30-0.1 ± 2.06-0.8 ± 2.02-0.8 ± 2.14-0.3 ± 2.14
Sodium; Week 14; n=33,35,32,34,31,290.2 ± 1.97-0.6 ± 1.75-0.2 ± 2.34-1.0 ± 2.00-0.7 ± 2.22-0.1 ± 1.93
Sodium; EW; n=3,3,7,3,11,11-1.3 ± 1.15-1.3 ± 2.08-2.0 ± 1.00-0.3 ± 0.580.1 ± 1.580.5 ± 2.34
BUN; Week 2; n= 38,39,38,39,33,32-0.38 ± 1.205-0.33 ± 1.0780.03 ± 1.0260.10 ± 1.0010.29 ± 1.256-0.19 ± 1.098
BUN; Week 4; n=38,39,38,38,30,32-0.38 ± 1.142-0.21 ± 1.2760.00 ± 1.202-0.08 ± 1.0940.10 ± 1.367-0.11 ± 1.091
BUN; Week 8; n= 35,37,34,38,29,28-0.27 ± 1.2510.08 ± 1.199-0.03 ± 0.807-0.18 ± 1.0990.17 ± 1.1590.02 ± 1.572
BUN; Week 12; n= 36,37,32,35,28,28-0.38 ± 1.250-0.09 ± 1.767-0.05 ± 1.0800.07 ± 1.0300.23 ± 1.3840.07 ± 1.614
BUN; Week 14; n=33,35,32,34,31,290.02 ± 1.3610.21 ± 1.5400.19 ± 1.1480.15 ± 1.2090.02 ± 1.2680.19 ± 1.429
BUN; EW; n= 3,3,7,3,11,11-0.33 ± 0.577-0.50 ± 1.000-0.36 ± 1.144-1.00 ± 0.8660.50 ± 0.775-0.23 ± 1.915
SecondaryNumber of Participants With Chemistry Data of Potential Clinical Importance

Blood samples were collected from participants for evaluation of clinical chemistry parameters by Potential Clinical Importance Criteria from Baseline to Week 14, EW and any visit post-screen. The vital signs included alk.phosph., ALT, AST, bilirubin, calcium, CO2, creatinine, glucose and potassium. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Time frame:
Week 2, 4, 8, 12, 14, EW (up to week 14)
Reported as:
Number · Participants
Number of Participants With Chemistry Data of Potential Clinical Importance
ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Alk.Phosph;Baseline; n= 40,41,43,41,42,40000000
Alk.Phosph; Week 2; n= 38,39,38,39,33,32100000
Alk.Phosph.; Week 4; n= 38,39, 38,38,30,32000000
Alk.Phosph.; Week 8; n= 35, 37, 34, 38, 29, 28100000
Alk.Phosph.; Week 12; n= 36, 37, 32, 35, 28, 28100000
Alk.Phosph.; Week 14; n= 33, 35, 32, 34, 31, 29000000
Alk.Phosph.; EW; n= 3, 3, 7, 3, 11, 11000000
Alk. Phosph.; post-screen; n= 40, 40,40,39,39,40100000
ALT; Baseline; n= 40,41,43,41,42,40000000
ALT; Week 2; n= 38,39,38,39,33,32101000
ALT; Week 4; n= 38,39, 38,38,30,32000000
ALT; Week 8; n=35, 37, 34, 38, 29, 28100000
ALT; Week 12; n= 36, 37, 32, 35, 28, 28100000
ALT; Week 14; n=33, 35, 32, 34, 31, 29100000
ALT; EW; n= 3, 3, 7, 3, 11, 11001000
ALT; post-screen; n= 40, 40,40,39,39,40202000
AST; Baseline; n= 40,41,43,41,42,40000000
AST; Week 2; n=38,39,38,39,33,32000000
AST; Week 4; n= 38,39, 38,38,30,32000000
AST; Week 8; n= 35, 37, 34, 38, 29, 28200000
AST; Week 12; n= 36, 37, 32, 35, 28, 28000000
AST; Week 14; n= 33, 35, 32, 34, 31, 29200000
AST; EW; n= 3, 3, 7, 3, 11, 11000000
AST; Post-screen; n= 40, 40,40,39,39,40400000
Bilirubin; Baseline; n= 40,41,43,41,42,40000010
Bilirubin; Week 2; n= 38,39,38,39,33,32000000
Bilirubin; Week 4; n= 38,39, 38,38,30,32000001
Bilirubin; Week 8; n= 35, 37, 34, 38, 29, 28000000
Bilirubin; Week 12; n=36, 37, 32, 35, 28, 28000000
Bilirubin; Week 14; n= 33, 35, 32, 34, 31, 29001000
Bilirubin; EW; n= 3, 3, 7, 3, 11, 11000000
Bilirubin; post-screen; n= 40, 40,40,39,39,40001001
Calcium; Baseline; n= 40,41,43,41,42,40000000
Calcium; Week 2; n=38,39,38,39,33,32000000
Calcium; Week 4; n= 38,39, 38,38,30,32000000
Calcium; Week 8; n= 35, 37, 34, 38, 29, 28000000
Calcium; Week 12; n= 36, 37, 32, 35, 28, 28000000
Calcium; Week 14; n= 33, 35, 32, 34, 31, 29001000
Calcium; EW; n= 3, 3, 7, 3, 11, 11000000
Calcium; post-screen; n= 40, 40,40,39,39,40001000
CO2; Baseline; n= 40,41,43,41,42,40010100
CO2; Week 2; n=38,39,38,39,33,32111001
CO2; Week 4; n= 38,39, 38,38,30,32001000
CO2; Week 8; n= 35, 37, 34, 38, 29, 28110102
CO2; Week 12; n= 36, 37, 32, 35, 28, 28000100
CO2; Week 14; n= 33, 35, 32, 34, 31, 29102110
CO2; EW; n= 3, 3, 7, 3, 11, 11000000
CO2; Post-screen; n= 40, 40,40,39,39,40324313
Creatinine; Baseline; n= 40,41,43,41,42,40000000
Creatinine; Week 2; n= 38,39,38,39,33,32000000
Creatinine; Week 4; n= 38,39, 38,38,30,32000001
Creatinine; Week 8; n= 35, 37, 34, 38, 29, 28000000
Creatinine; Week 12; n= 36, 37, 32, 35, 28, 28000000
Creatinine; Week 14; n= 33, 35, 32, 34, 31, 29000000
Creatinine; EW; n= 3, 3, 7, 3, 11, 11000000
Creatinine; post-screen; n= 40, 40,40,39,39,40000001
Glucose; Baseline; n= 40,41,43,41,42,40012212
Glucose; Week 2; n= 38,39,38,39,33,32220302
Glucose; Week 4; n= 38,39, 38,38,30,32110203
Glucose; Week 8; n=35, 37, 34, 38, 29, 28121202
Glucose; Week 12; n= 36, 37, 32, 35, 28, 28211102
Glucose; Week 14; n= 33, 35, 32, 34, 31, 29020301
Glucose; EW; n= 3, 3, 7, 3, 11, 11000100
Glucose; post-screen; n= 40, 40,40,39,39,40441605
Potassium; Baseline; n= 40,41,43,41,42,40000000
Potassium; Week 2; n= 38,39,38,39,33,32000110
Potassium; Week 4; n= 38,39, 38,38,30,32002000
Potassium; Week 8; n= 35, 37, 34, 38, 29, 28001000
Potassium; n= Week 12; n= 36, 37, 32, 35, 28, 28000000
Potassium; Week 14; n= 33, 35, 32, 34, 31, 29001010
Potassium;EW; n= 3, 3, 7, 3, 11, 11000000
Potassium; post-screen; n= 40, 40,40,39,39,40002110
SecondaryChange From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet, Leukocytes Count

Blood samples were collected to evaluate change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet and leukocytes and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

Time frame:
Week 2, 4, 8, 12, 14, EW (up to week 14)
Reported as:
Mean · Giga cells per liter (GI/L)
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet, Leukocytes Count
Giga cells per liter (GI/L)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Basophils; Week 2; n= 37,38,38,37,33,31-0.006 ± 0.0177-0.001 ± 0.0205-0.000 ± 0.0201-0.002 ± 0.0175-0.004 ± 0.01660.000 ± 0.0176
Basophils; Week 4; n= 38,38,38,37,30,31-0.002 ± 0.01950.000 ± 0.02010.005 ± 0.0241-0.000 ± 0.0191-0.006 ± 0.01920.006 ± 0.0218
Basophils; Week 8; n= 34,36,34,37,29,27-0.004 ± 0.0224-0.001 ± 0.02140.000 ± 0.0165-0.007 ± 0.0161-0.005 ± 0.02180.004 ± 0.0162
Basophils; Week 12; n= 36,36,32,34,28,270.001 ± 0.01660.002 ± 0.01910.005 ± 0.02440.003 ± 0.03430.003 ± 0.03480.010 ± 0.0236
Basophils; Week 14; n= 33,33,32,32,31,27-0.001 ± 0.0160-0.000 ± 0.01900.003 ± 0.0202-0.003 ± 0.02260.008 ± 0.0312-0.001 ± 0.0188
Basophils; EW; n= 3,3,7,3,10,10-0.000 ± 0.01730.020 ± 0.01000.007 ± 0.01800.017 ± 0.01150.011 ± 0.0110-0.005 ± 0.0264
Eosinophils; Week 2; n=37,38,38,37,33,31-0.035 ± 0.21530.012 ± 0.1629-0.092 ± 0.2733-0.018 ± 0.23250.064 ± 0.43970.052 ± 0.1474
Eosinophils; Week 4; n=38,38,38,37,30,31-0.075 ± 0.3146-0.049 ± 0.2401-0.119 ± 0.3926-0.034 ± 0.21430.063 ± 0.47290.057 ± 0.1644
Eosinophils; Week 8; n=34,36,34,37,29,27-0.052 ± 0.3486-0.040 ± 0.1398-0.107 ± 0.3276-0.034 ± 0.22710.009 ± 0.19230.106 ± 0.2805
Eosinophils; Week 12; n= 36,36,32,34,28,27-0.083 ± 0.3212-0.026 ± 0.1811-0.120 ± 0.3025-0.063 ± 0.1751-0.028 ± 0.21760.033 ± 0.1606
Eosinophils; Week 14; n= 33,33,32,32,31,27-0.078 ± 0.3178-0.043 ± 0.2237-0.104 ± 0.2377-0.056 ± 0.1493-0.041 ± 0.21070.038 ± 0.1779
Eosinophils; EW; n=3,3,7,3,10,100.113 ± 0.15010.117 ± 0.1680-0.220 ± 0.31140.047 ± 0.06430.065 ± 0.19050.062 ± 0.3301
Lymphocytes; Week 2; n= 37,38,38,37,33,310.035 ± 0.46720.076 ± 0.52390.123 ± 0.52630.064 ± 0.35100.030 ± 0.47240.018 ± 0.4654
Lymphocytes; Week 4; n= 38,38,38,37,30,310.054 ± 0.52640.217 ± 0.52920.083 ± 0.58940.021 ± 0.4099-0.078 ± 0.48740.151 ± 0.5349
Lymphocytes; Week 8; n= 34,36,34,37,29,270.100 ± 0.39530.165 ± 0.62130.012 ± 0.4463-0.031 ± 0.3914-0.018 ± 0.52850.166 ± 0.4024
Lymphocytes; Week 12; n= 36,36,32,34,28,270.045 ± 0.48060.232 ± 0.62580.061 ± 0.57580.072 ± 0.4836-0.034 ± 0.57790.116 ± 0.3819
Lymphocytes; Week 14; n= 33,33,32,32,31,270.030 ± 0.48690.146 ± 0.5891-0.093 ± 0.60480.195 ± 0.5632-0.035 ± 0.57570.184 ± 0.3451
Lymphocytes; EW; n= 3,3,7,3,10,10-0.317 ± 0.53150.040 ± 0.0954-0.136 ± 0.46440.450 ± 0.0755-0.021 ± 0.4694-0.225 ± 0.4165
Monocytes; Week 2; n=37,38,38,37,33,31-0.028 ± 0.1465-0.025 ± 0.12710.013 ± 0.16590.008 ± 0.0965-0.028 ± 0.14150.019 ± 0.1948
Monocytes; Week 4; n= 38,38,38,37,30,31-0.004 ± 0.1769-0.023 ± 0.1230-0.059 ± 0.16480.006 ± 0.1151-0.047 ± 0.16110.010 ± 0.1419
Monocytes; Week 8; n= 34,36,34,37,29,27-0.071 ± 0.1443-0.041 ± 0.1224-0.032 ± 0.1355-0.012 ± 0.1359-0.066 ± 0.1465-0.001 ± 0.1171
Monocytes; Week 12; n=36,36,32,34,28,27-0.061 ± 0.1653-0.022 ± 0.1219-0.042 ± 0.1539-0.019 ± 0.1434-0.078 ± 0.17360.007 ± 0.1801
Monocytes; Week 14; n=33,33,32,32,31,27-0.026 ± 0.15320.027 ± 0.1427-0.016 ± 0.14460.015 ± 0.1666-0.093 ± 0.14970.035 ± 0.1821
Monocytes; EW; n=3,3,7,3,10,10-0.127 ± 0.09240.007 ± 0.08500.030 ± 0.11330.040 ± 0.0608-0.018 ± 0.0966-0.159 ± 0.1672
Neutrophils; Week 2; n=37,38,38,37,33,310.480 ± 1.79530.152 ± 1.00580.067 ± 1.7035-0.088 ± 1.4680-0.097 ± 1.8249-0.258 ± 1.2803
Neutrophils; Week 4; n=38,38,38,37,30,310.487 ± 2.04250.253 ± 1.1437-0.058 ± 1.70280.035 ± 1.3063-0.141 ± 2.10240.100 ± 1.4283
Neutrophils; Week 8; n= 34,36,34,37,29,270.009 ± 1.4215-0.203 ± 1.0365-0.083 ± 1.44540.550 ± 1.5918-0.432 ± 1.59710.214 ± 1.1894
Neutrophils; Week 12; n= 36,36,32,34,28,270.127 ± 1.3363-0.009 ± 1.13150.049 ± 1.42940.237 ± 1.1459-0.348 ± 1.55140.328 ± 1.6786
Neutrophils; Week 14; n=33,33,32,32,31,270.090 ± 1.20370.164 ± 1.2465-0.368 ± 1.0224-0.058 ± 1.5202-0.155 ± 1.9840-0.013 ± 1.4826
Neutrophils; EW; n=3,3,7,3,10,10-0.420 ± 0.99240.047 ± 0.74780.797 ± 2.15060.630 ± 1.0741-0.331 ± 1.23060.158 ± 1.8160
Platelet; Week 2; n=37,38,38,37,33,31-15.4 ± 44.06-18.7 ± 36.48-25.9 ± 43.03-20.2 ± 30.63-0.5 ± 31.186.9 ± 31.60
Platelet; Week 4; n=38,38,38,37,30,31-12.4 ± 36.57-19.7 ± 36.44-25.2 ± 35.75-7.7 ± 38.40-2.4 ± 30.4812.7 ± 29.38
Platelet; Week 8; n= 34,36,34,37,29,27-6.2 ± 34.81-9.1 ± 51.69-22.1 ± 37.57-11.5 ± 44.801.4 ± 37.708.8 ± 39.83
Platelet; Week 12; n=36,36,32,34,28,27-7.5 ± 37.94-5.4 ± 30.15-23.6 ± 38.11-18.9 ± 38.67-4.6 ± 35.71-6.8 ± 24.06
Platelet; Week 14; n=33,33,32,32,31,273.5 ± 40.84-9.0 ± 38.20-19.9 ± 44.95-8.2 ± 47.605.1 ± 31.346.5 ± 51.77
Platelet; EW; n=3,3,7,3,10,10-85.0 ± 11.0012.7 ± 56.01-19.7 ± 25.7711.7 ± 18.568.4 ± 24.5611.3 ± 59.83
Leukocytes; Week 2; n=37,38,38,37,33,310.45 ± 1.7490.21 ± 1.0850.10 ± 1.668-0.02 ± 1.585-0.05 ± 1.972-0.16 ± 1.624
Leukocytes; Week 4; n= 38,38,38,37,30,310.46 ± 1.9130.40 ± 1.232-0.15 ± 1.8070.03 ± 1.517-0.21 ± 2.2210.34 ± 1.694
Leukocytes; Week 8; n=34,36,34,37,29,270.03 ± 1.466-0.12 ± 1.257-0.21 ± 1.5670.47 ± 1.469-0.52 ± 1.7210.49 ± 1.113
Leukocytes; Week 12; n=36,36,32,34,28,270.03 ± 1.4880.18 ± 1.249-0.05 ± 1.3710.23 ± 1.248-0.49 ± 1.4560.49 ± 1.776
Leukocytes; Week 14; n=33,33,32,32,31,270.02 ± 1.2340.30 ± 1.200-0.57 ± 1.1420.10 ± 1.705-0.32 ± 2.1210.23 ± 1.498
Leukocytes; EW; n= 3,3,7,3,10,10-0.73 ± 0.6660.23 ± 1.1150.47 ± 2.3941.20 ± 1.127-0.29 ± 1.454-0.16 ± 2.151
SecondaryChange From Baseline in Hematocrit Levels

Blood samples were collected to evaluate change from Baseline in hematocrit and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

Time frame:
Week 2, 4, 8, 12, 14, EW (up to week 14)
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematocrit Levels
Proportion of red blood cells in bloodGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 2; n= 37,38,38,37,33,31-0.0054 ± 0.0276-0.0132 ± 0.0195-0.0138 ± 0.0260-0.0116 ± 0.0246-0.0014 ± 0.0267-0.0095 ± 0.0239
Week 4; n= 38,38,38,37,30,31-0.0107 ± 0.0315-0.0075 ± 0.0241-0.0081 ± 0.0253-0.0075 ± 0.0233-0.0090 ± 0.0283-0.0123 ± 0.0295
Week 8; n=34,36,34,37,29,27-0.0066 ± 0.0316-0.0148 ± 0.0225-0.0091 ± 0.0225-0.0042 ± 0.0235-0.0011 ± 0.0264-0.0124 ± 0.0314
Week 12; n= 36,36,32,34,28,27-0.0054 ± 0.0302-0.0129 ± 0.0222-0.0131 ± 0.0205-0.0106 ± 0.0227-0.0052 ± 0.0312-0.0111 ± 0.0240
Week 14; n= 33,33,32,32,31,28-0.0151 ± 0.0292-0.0170 ± 0.0236-0.0132 ± 0.0193-0.0063 ± 0.0286-0.0007 ± 0.0277-0.0117 ± 0.0292
EW; n= 3,3,7,3,10,100.0037 ± 0.0123-0.0063 ± 0.0352-0.0174 ± 0.0292-0.0117 ± 0.01330.0027 ± 0.01520.0048 ± 0.0248
SecondaryChange From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC)

Blood samples were collected to evaluate change from Baseline in hemoglobin and MCHC and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

Time frame:
Week 2, 4, 8, 12, 14, EW (up to week 14)
Reported as:
Mean · G/L
Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC)
G/LGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Hemoglobin; Week 2; n= 37,38,38,37,33,31-1.8 ± 9.02-3.8 ± 5.54-4.3 ± 8.08-2.8 ± 6.78-0.9 ± 8.76-3.0 ± 6.55
Hemoglobin; Week 4; n= 38,38,38,37,30,31-3.2 ± 8.88-2.7 ± 6.42-3.5 ± 7.72-2.4 ± 6.27-3.0 ± 9.17-4.1 ± 9.05
Hemoglobin; Week 8; n=34,36,34,37,29,27-2.7 ± 9.64-4.6 ± 6.43-3.7 ± 6.90-1.6 ± 6.70-0.8 ± 7.59-4.6 ± 9.72
Hemoglobin; Week 12; n= 36,36,32,34,28,27-2.3 ± 9.33-4.2 ± 6.61-5.2 ± 6.77-3.1 ± 5.58-2.5 ± 9.52-4.4 ± 6.63
Hemoglobin; Week 14; n= 33,33,32,32,31,28-5.5 ± 9.25-3.9 ± 6.76-5.2 ± 6.73-1.8 ± 8.17-0.8 ± 8.51-4.0 ± 7.93
Hemoglobin; EW; n= 3,3,7,3,10,100.7 ± 11.59-1.3 ± 11.59-6.0 ± 8.47-2.0 ± 9.000.0 ± 3.77-1.1 ± 5.69
MCHC; Week 2; n= 37,38,38,37,33,310.1 ± 7.470.9 ± 7.830.8 ± 6.652.0 ± 10.23-1.4 ± 8.378.37 ± 8.92
MCHC; Week 4; n= 38,38,38,37,30,310.9 ± 8.89-0.3 ± 9.51-1.9 ± 9.530.2 ± 9.620.0 ± 9.140.1 ± 8.17
MCHC; Week 8; n=34,36,34,37,29,27-1.1 ± 9.280.4 ± 11.61-1.9 ± 8.69-0.5 ± 11.02-0.5 ± 10.28-1.3 ± 8.96
MCHC; Week 12; n= 36,36,32,34,28,27-1.0 ± 10.230.1 ± 11.12-2.5 ± 10.950.9 ± 10.85-1.4 ± 10.77-1.8 ± 9.95
MCHC; Week 14; n= 33,33,32,32,31,28-1.2 ± 11.153.9 ± 10.96-2.2 ± 10.240.7 ± 10.42-1.0 ± 11.18-0.1 ± 8.59
MCHC; EW; n= 3,3,7,3,10,10-1.7 ± 20.261.7 ± 2.52-1.1 ± 10.643.3 ± 12.86-2.2 ± 5.25-6.6 ± 9.09
SecondaryChange From Baseline in Mean Corpuscle Hemoglobin (MCH)

Blood samples were collected to evaluate change from Baseline in MCH and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

Time frame:
Week 2, 4, 8, 12, 14, EW (up to week 14)
Reported as:
Mean · Picogram (Pg)
Change From Baseline in Mean Corpuscle Hemoglobin (MCH)
Picogram (Pg)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 2; n= 37,38,38,37,33,310.05 ± 0.4250.09 ± 0.5950.06 ± 0.4080.19 ± 0.6670.04 ± 0.4150.05 ± 0.490
Week 4; n= 38,38,38,37,30,310.09 ± 0.5350.06 ± 0.593-0.01 ± 0.5190.15 ± 0.5670.06 ± 0.518-0.05 ± 0.528
Week 8; n=34,36,34,37,29,270.03 ± 0.6350.21 ± 0.747-0.06 ± 0.5360.22 ± 0.7810.02 ± 0.599-0.07 ± 0.640
Week 12; n= 36,36,32,34,28,270.14 ± 0.7080.14 ± 0.7900.10 ± 0.5060.30 ± 0.8150.04 ± 0.5880.06 ± 0.806
Week 14; n= 33,33,32,32,31,280.06 ± 0.9000.55 ± 0.8060.08 ± 0.4490.28 ± 0.6120.06 ± 0.804-0.01 ± 0.589
EW; n= 3,3,7,3,10,100.57 ± 1.3610.03 ± 0.702-0.19 ± 0.5960.63 ± 0.808-0.13 ± 0.933-0.15 ± 0.542
SecondaryChange From Baseline in Mean Corpuscle Volume (MCV)

Blood samples were collected to evaluate change from Baseline in MCV and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

Time frame:
Week 2, 4, 8, 12, 14, EW (up to week 14)
Reported as:
Mean · Femtoliter (fL)
Change From Baseline in Mean Corpuscle Volume (MCV)
Femtoliter (fL)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 2; n= 37,38,38,37,33,310.2 ± 2.02-0.2 ± 1.45-0.1 ± 1.47-0.1 ± 2.370.5 ± 1.870.1 ± 1.83
Week 4; n= 38,38,38,37,30,310.1 ± 1.750.2 ± 2.040.5 ± 1.940.4 ± 2.800.1 ± 1.90-0.3 ± 1.85
Week 8; n=34,36,34,37,29,270.5 ± 2.420.5 ± 2.520.4 ± 1.780.7 ± 2.900.2 ± 2.390.0 ± 2.01
Week 12; n= 36,36,32,34,28,270.8 ± 2.800.3 ± 2.681.0 ± 2.620.6 ± 3.200.5 ± 3.060.5 ± 1.99
Week 14; n= 33,33,32,32,31,280.6 ± 2.920.4 ± 2.540.9 ± 2.540.7 ± 2.370.4 ± 3.19-0.1 ± 2.25
EW; n= 3,3,7,3,10,101.7 ± 1.53-0.7 ± 2.08-0.4 ± 2.151.0 ± 1.00-0.1 ± 2.811.4 ± 2.59
SecondaryChange From Baseline in Erythrocyte Count

Blood samples were collected to evaluate change from Baseline in erythrocytes and values at Baseline throughout the 12 weeks of study treatment and follow up visit 1 at Week 14. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

Time frame:
Weeks 2, 4, 8, 12, 14, EW (week up to 14)
Reported as:
Mean · Tetra cells per liter (TI/L)
Change From Baseline in Erythrocyte Count
Tetra cells per liter (TI/L)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 2; n= 37,38,38,37,33,31-0.06 ± 0.325-0.16 ± 0.218-0.15 ± 0.287-0.12 ± 0.260-0.03 ± 0.293-0.12 ± 0.241
Week 4; n= 38,38,38,37,30,31-0.12 ± 0.347-0.10 ± 0.256-0.13 ± 0.273-0.10 ± 0.215-0.11 ± 0.317-0.13 ± 0.312
Week 8; n=34,36,34,37,29,27-0.10 ± 0.371-0.21 ± 0.227-0.12 ± 0.265-0.08 ± 0.205-0.03 ± 0.268-0.14 ± 0.318
Week 12; n= 36,36,32,34,28,27-0.09 ± 0.345-0.18 ± 0.244-0.21 ± 0.250-0.15 ± 0.191-0.09 ± 0.314-0.15 ± 0.262
Week 14; n= 33,33,32,32,31,28-0.20 ± 0.342-0.22 ± 0.262-0.21 ± 0.229-0.10 ± 0.261-0.03 ± 0.330-0.14 ± 0.312
EW; n= 3,3,7,3,10,10-0.03 ± 0.252-0.07 ± 0.321-0.19 ± 0.297-0.13 ± 0.1530.04 ± 0.246-0.03 ± 0.267
SecondaryNumber of Participants With Hematology Data of Potential Clinical Importance

Blood samples were collected from participants for evaluation of hematology parameters by Potential Clinical Importance Criteria from Baseline to Week 14, EW and any visit post-screen. The vital signs included hematocrit, hemoglobin, lymphocytes, neutrophils, platelet and leukocytes. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Time frame:
Baseline, Week 2, 4, 8, 12, 14, early withdrawal, and post screen (up to Week 16)
Reported as:
Number · Participants
Number of Participants With Hematology Data of Potential Clinical Importance
ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Hematocrit; Baseline; n= 40, 40, 43, 40, 42, 39000000
Hematocrit; Week 2; n= 37, 39, 38, 38, 33, 31000010
Hematocrit; Week 4; n= 38, 39, 38,38,30,32000001
Hematocrit; Week 8; n=34,36,34,38,29,28101011
Hematocrit; Week 12; n= 36, 37, 32, 35, 28,28100000
Hematocrit; Week 14; n= 33,34,32,33,31,29100002
Hematocrit; EW; n= 3,3,7,3,10,10000000
Hematocrit; post-screen; n= 40,40,40,39,39,40201012
Hemoglobin; Baseline;n= 40, 40, 43, 40, 42, 39000000
Hemoglobin; Week 2; n= 37, 39, 38, 38, 33, 31000000
Hemoglobin; Week 4; n= 38, 39, 38,38,30,32000001
Hemoglobin; Week 8; n= 34,36,34,38,29,28100001
Hemoglobin; Week 12; n= 36, 37, 32, 35, 28,28000000
Hemoglobin; Week 14; n=33,34,32,33,31,29000000
Hemoglobin; EW; n= 3,3,7,3,10,10000000
Hemoglobin; post-screen; n= 40,40,40,39,39,40100001
Lymphocytes;Baseline; n= 40, 40, 43, 40, 42, 39011001
Lymphocytes; Week 2; n= 37, 39, 38, 38, 33, 31010000
Lymhocytes; Week 4; n= 38, 39, 38,38,30,32000000
Lymphocytes; Week 8; n= 34,36,34,38,29,28000000
Lymphocytes; Week 12; n=36, 37, 32, 35, 28,28000010
Lymphocytes; Week 14; n= 33,34,32,33,31,28000000
Lymphocytes; EW;n= 3,3,7,3,10,10000000
Lymphocytes; post-screen; n= 40,40,40,39,39,40010010
Neutrophils; Baseline; n= 40, 40, 43, 40, 42, 39200000
Neutrophils; Week 2; n= 37, 39, 38, 38, 33, 31010100
Neutrophils; Week 4; n= 38, 39, 38,38,30,32401000
Neutrophils; Week 8; n= 34,36,34,38,29,28010000
Neutrophils; Week 12; n= 36, 37, 32, 35, 28,28000000
Neutrophils; Week 14; n=33,34,32,33,31,29000000
Neutrophils; EW; n=3,3,7,3,10,10010000
Neutrophils; post-screen;n= 40,40,40,39,39,40421100
Platelets; Baseline; n= 40, 40, 43, 40, 42, 39000000
Platelets; Week 2; n= :37,38,38,38,33,31000000
Platelets; Week 4; n=37,39, 38,38,30,32000010
Platelets; Week 8; n= 34,36,34,38,29,28000000
Platelets; Week 12; n= 35,37,32,35,28,28000000
Platelets; Week 14; n=33,34,32,33,31,29000001
Platelets; EW; n=3,3,7,3,10,10000000
Platelets; post-screen; n= 40,40,40,39,39,40000011
Leukocytes; Baseline; n= 40, 40, 43, 40, 42, 39000000
Leukocytes; Week 2; n=37, 39, 38, 38, 33, 31010100
Leukocytes; Week 4; n=38, 39, 38,38,30,32000000
Leukocytes; Week 8; n=34,36,34,38,29,28000000
Leukocytes; Week 12; n= 36, 37, 32, 35, 28,28000000
Leukocytes; Week 14; n=33,34,32,33,31,28000000
Leukocytes; n= EW; n=3,3,7,3,10,10000000
Leukocytes; post-screen; n= 40,40,40,39,39,40010100
SecondaryChange From Baseline in Total T Lymphocytes (Lympho), B Lympho, Natural Killer (NK) Lymphocytes and Treg (Foxp3) Levels

Blood samples were collected to evaluate change from Baseline in total T lympho, B lympho, T and B NK cells and (Foxp3) values at Baseline throughout the 12 weeks of study treatment. The immunophenotyping parameters included cluster of differentiation (CD)19, CD3, CD3+CD8+, CD3+CD4+, CD16+CD56+, CD3+CD4+CD25+CD127, CD3+CD4+foxP3+CD25+CD127 and T and NK lympho. CD3, CD3+CD8+ and CD3+CD4+ were also evaluated by using treg flow cytometry (cyto). Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

Time frame:
Week, 4, 8 and 12
Reported as:
Mean · GI/L
Change From Baseline in Total T Lymphocytes (Lympho), B Lympho, Natural Killer (NK) Lymphocytes and Treg (Foxp3) Levels
GI/LGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
CD19; Week 4; n= 37,38,38,37,29,320.0394 ± 0.11490.0407 ± 0.12290.0068 ± 0.15320.0174 ± 0.0933-0.0217 ± 0.14100.0406 ± 0.1114
CD19; Week 8; n=34,37,34,37,28,270.0273 ± 0.09510.0343 ± 0.14800.0122 ± 0.1154-0.0006 ± 0.1099-0.0282 ± 0.15020.0367 ± 0.0966
CD19; Week 12; n= 35,37,32,34,27,270.0111 ± 0.12620.0647 ± 0.14400.0317 ± 0.10770.0224 ± 0.0927-0.0439 ± 0.13500.0041 ± 0.1009
CD3; Week 4; n= 37,38,38,37,29,32-0.0050 ± 0.38300.0867 ± 0.38090.0842 ± 0.33430.0108 ± 0.3364-0.0397 ± 0.45050.1678 ± 0.3583
CD3; Week 8; n=34,37,34,37,28,270.0523 ± 0.31170.0581 ± 0.44960.0334 ± 0.3855-0.0593 ± 0.3172-0.0350 ± 0.44030.1066 ± 0.3531
CD3; Week 12; n= 35,37,32,34,27,27-0.0045 ± 0.42540.1312 ± 0.40330.1375 ± 0.40030.0071 ± 0.2729-0.1338 ± 0.50230.0167 ± 0.2879
CD3 treg flow cyto; Week 4; n= 35,37,36,35,28,28-0.0277 ± 0.39120.0643 ± 0.39880.0682 ± 0.28530.0270 ± 0.3320-0.0688 ± 0.47640.1943 ± 0.3722
CD3; treg flow cyto; Week 8; n=31,35,32,36,27,250.0184 ± 0.29290.0745 ± 0.4592-0.0023 ± 0.3513-0.0647 ± 0.3128-0.0626 ± 0.46790.1302 ± 0.3505
CD3; treg flow cyto; Week 12; n= 32,36,31,32,25,24-0.0215 ± 0.41200.1418 ± 0.43180.1171 ± 0.4070-0.0063 ± 0.2771-0.1402 ± 0.54500.0028 ± 0.3101
CD3+CD8+; Week 4; n= 37,38,38,37,29,32-0.0272 ± 0.20770.0248 ± 0.12980.0282 ± 0.12660.0147 ± 0.1194-0.0155 ± 0.16080.0526 ± 0.1388
CD3+CD8+; Week 8; n= 34,37,34,37,28,27-0.0048 ± 0.13370.0011 ± 0.15610.0242 ± 0.1335-0.0263 ± 0.1145-0.0315 ± 0.16770.0322 ± 0.1721
CD3+CD8+; Week 12;n=35,37,32,34,27,27-0.0307 ± 0.17540.0270 ± 0.13920.0357 ± 0.1578-0.0115 ± 0.0868-0.0853 ± 0.1818-0.0023 ± 0.1097
CD3+CD8+ treg flow cyto;Week 4;n=35,37,36,35,28,28-0.0392 ± 0.21240.0211 ± 0.12220.0004 ± 0.11170.0038 ± 0.1112-0.0246 ± 0.15720.0728 ± 0.1175
CD3+CD8+ treg flow cyto;Week 8;n=31,35,32,36,27,250.0004 ± 0.12280.0125 ± 0.1350-0.0008 ± 0.1214-0.0376 ± 0.1150-0.0351 ± 0.16720.0484 ± 0.1417
CD3+CD8+treg flow cyto;Week12;n=32,36,31,32,25,24-0.0179 ± 0.17380.0311 ± 0.13380.0151 ± 0.1490-0.0230 ± 0.0865-0.0689 ± 0.17520.0120 ± 0.1064
CD3+CD4+; Week 4; n= 37,38,38,37,29,320.0080 ± 0.20660.0579 ± 0.25320.0562 ± 0.2652-0.0030 ± 0.2342-0.0268 ± 0.29130.1138 ± 0.2308
CD3+CD4+; Week 8; n=34,37,34,37,28,270.0282 ± 0.17390.0539 ± 0.29960.0072 ± 0.2794-0.0287 ± 0.2054-0.0015 ± 0.28030.0778 ± 0.1826
CD3+CD4+; Week 12; n= 35,37,32,34,27,270.0243 ± 0.25510.0957 ± 0.27130.1087 ± 0.27950.0216 ± 0.1929-0.0465 ± 0.33380.0181 ± 0.1872
CD3+CD4+ treg flow cyto;Week 4;n=35,37,36,35,28,280.0117 ± 0.20480.0575 ± 0.25710.0825 ± 0.18750.0135 ± 0.2167-0.0229 ± 0.28780.1215 ± 0.2442
CD3+CD4+ treg flow cyto;Week 8;n=31,35,32,36,27,250.0286 ± 0.17440.0687 ± 0.2923-0.0158 ± 0.2536-0.0284 ± 0.2018-0.0007 ± 0.27510.0849 ± 0.1883
CD3+CD4+treg flow cyto;Week 12;n=32,36,31,32,25,240.0235 ± 0.25080.1058 ± 0.27180.0979 ± 0.26910.0141 ± 0.1885-0.0403 ± 0.33310.0213 ± 0.1940
CD16+CD56+; Week 4; n=37,38,38,37,29,32-0.021 ± 0.0942-0.018 ± 0.0752-0.019 ± 0.0976-0.004 ± 0.1057-0.009 ± 0.08370.016 ± 0.0999
CD16+CD56+; Week 8; n=34,37,34,37,28,27-0.013 ± 0.0909-0.012 ± 0.1594-0.016 ± 0.1045-0.009 ± 0.0919-0.029 ± 0.0860-0.012 ± 0.1131
CD16+CD56+; Week 12; n= 35,37,32,34,27,27-0.038 ± 0.0884-0.021 ± 0.0911-0.022 ± 0.0792-0.036 ± 0.0702-0.039 ± 0.0909-0.020 ± 0.0888
CD3+CD4+CD25+CD127; Week4;n=35,37,36,35,28,280.0006 ± 0.01390.0023 ± 0.01500.0022 ± 0.01720.0005 ± 0.0174-0.0050 ± 0.01790.0098 ± 0.0345
CD3+CD4+CD25+CD127; Week8;n=31,35,32,36,27,250.0044 ± 0.01990.0062 ± 0.01670.0026 ± 0.02230.0029 ± 0.0196-0.0049 ± 0.01810.0054 ± 0.0222
CD3+CD4+CD25+CD127; Week12;n=32,36,31,32,25,240.0050 ± 0.01930.0056 ± 0.02280.0081 ± 0.02290.0054 ± 0.02170.0007 ± 0.02300.0055 ± 0.0215
CD3+CD4+foxP3+CD25+CD127;Week4;n=35,37,36,35,28,280.0009 ± 0.01250.0001 ± 0.01620.0009 ± 0.0129-0.0013 ± 0.01640.0008 ± 0.00990.0056 ± 0.0123
CD3+CD4+foxP3+CD25+CD127;Week8;n=31,35,32,35,27,250.0070 ± 0.01840.0011 ± 0.01470.0021 ± 0.0182-0.0015 ± 0.01510.0032 ± 0.01510.0047 ± 0.0166
CD3+CD4+foxP3+CD25+CD127Week12;n=32,36,31,32,25,240.0076 ± 0.01490.0003 ± 0.01980.0052 ± 0.0192-0.0012 ± 0.01800.0039 ± 0.01600.0059 ± 0.0127
T &B cell NK lympho; Week4;n=37,38,38,37,29,320.009 ± 0.54610.101 ± 0.52870.092 ± 0.51220.021 ± 0.4664-0.082 ± 0.62060.228 ± 0.5116
T &B cell NK lympho;Week8;n=34,37,34,37,28,270.059 ± 0.44300.083 ± 0.67370.025 ± 0.5688-0.070 ± 0.4141-0.109 ± 0.62190.132 ± 0.5150
T &B cell NK lympho; Week12;n=35,37,32,34,27,27-0.041 ± 0.59220.174 ± 0.58250.140 ± 0.5609-0.009 ± 0.4041-0.236 ± 0.6830-0.001 ± 0.3842
SecondaryNumber of Participants With Immunopheotyping Data Outside the Reference Range

Blood samples were collected from participants for evaluation of immunophenotyping parameters by Potential Clinical Importance Criteria at Baseline, Week 4, Week 8, Week 12 nd any visit post-screen. The immunophenotyping parameters included CD 19, CD3, CD3+CD8+, CD3+CD4+, CD16+CD56+, CD3+CD4+CD25+CD127, CD3+CD4+foxP3+CD25+CD127 and T and NK lympho. CD3, CD3+CD8+ and CD3+CD4+ were also evaluated by using treg flow cyto. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Time frame:
Baseline, Week, 4, 8, 12 and post-screen (up to Week 16)
Reported as:
Number · Participants
Number of Participants With Immunopheotyping Data Outside the Reference Range
ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
CD19; Baseline; n=40,41,43,40,41,40005212
CD19; Week 4; n= 37,38,38,38,30,32305412
CD19; Week 8; n= 34,37,34,38,29,27213432
CD19; Week 12; n= 35,37,32,35,28,27133301
CD19; post-screen; n= 38,39,38,39,30,32437734
CD3; Baseline; n=40,41,43,41,41,40836143
CD3; Week 4; n=37,38,38,38,30,32636241
CD3; Week 8; n=34,37,34,38,29,27535224
CD3; Week 12; n=35,37,32,35,28,27425122
CD3; post-screen; n=38,39,38,39,30,32859467
CD3 treg flow cyto;Baseline; n=38,40,42,39,40,37000000
CD3 treg flow cyto; Week 4; n=37,38,37,37,30,30000000
CD3 treg flow cyto; Week8; n=33,36,33,38,29,26000000
CD3 treg flow cyto; Week 12; n= 34,37,32,34,27,25001000
CD3treg flow cyto; postscreen; n=38,39,38,39,30,32001000
CD3+CD8+; Baseline; n= 40,41,43,40,41,40933254
CD3+CD8+; Week 4; n=37,38,38,38,30,32534333
CD3+CD8+; Week 8; n=34,37,34,38,29,27424213
CD3+CD8+; Week 12; n= 35,37,32,35,28,27334114
CD3+CD8+; post-screen; n=38,39,38,39,30,32848456
CD3+CD8+tregflowcyto;Baseline;n= 38,40,42,39,40,37000000
CD3+CD8+tregflowcyto;Week4;n=37,38,37,37,30,30000000
CD3+CD8+tregflowcyto;Week8;n=33,36,33,38,29,26000000
CD3+CD8+tregflowcyto;Week12;n=34,37,32,34,27,25001000
CD3+CD8+tregflowcytopostscreen;n=38,39,38,39,30,32001000
CD3+CD4+; Baseline;n=40,41,43,40,41,40856342
CD3+CD4+; Week 4; n=37,38,38,38,30,32543331
CD3+CD4+; Week 8; n=34,37,34,38,29,27463563
CD3+CD4+; Week 12; n= 35,37,32,35,28,27565274
CD3+CD4+; post-screen;n=38,39,38,39,30,32887797
CD3+CD4+tregflow cyto;Baseline;n=38,40,42,39,40,37000000
CD3+CD4+tregflow cyto;Week4;n=37,38,37,37, 30,30000000
CD3+CD4+tregflow cyto;Week8;n=33,36,33,38,29,26000000
CD3+CD4+tregflow cyto;Week12;n=34,37,32,34,27,25001000
CD3+CD4+tregflow;postscreen;n=38,39,38,39,30,32001000
CD16+CD56+;Baseline;n=40,41,43,40,41,40112110
CD16+CD56+;Week4;n=37,38,38,38,30,32001111
CD16+CD56+;Week8;n=34,37,34,38,29,27121001
CD16+CD56+;Week12;n=35,37,32,35,28,27003000
CD16+CD56+;postscreen;n=38,39,38,39,30,32123111
CD3+CD4+CD25+CD127;Baseline;n=38,40,42,39,40,37000000
CD3+CD4+CD25+CD127;Week 4;n=37,38,37,37,30,30321341
CD3+CD4+CD25+CD127;Week8;n=33,36,33,38,29,26433624
CD3+CD4+CD25+CD127;Week12;n=34,37,32,34,27,25446655
CD3+CD4+CD25+CD127;postscreen;n=38,39,38,39,30,32768997
CD3+CD4+foxP3+CD25+CD127;Base;n=38,40,42,39,40,37000000
CD3+CD4+foxP3+CD25+CD127;Week4;n=37,38,37,37,30,30101071167
CD3+CD4+foxP3+CD25+CD127;Week8;n=33,36,33,37,29,269814969
CD3+CD4+foxP3+CD25+CD127;Week12;34,37,32,34,27,2510991486
CD3+CD4+foxP3+CD25+CD127;post;n=38,39,38,39,30,32191921221613
T-B cell NK lympho;Baseline; n=40,41,43,40,41,40112001
T-B cell NK lympho;Week4; n=37,38,38,38,30,32010020
T-B cell NK lympho;Week8;n=34,37,34,38,29,27011200
T-B cell NK lympho;Week12;n=35,37,32,35,28,27001030
T-B cell NK lympho;postscreen;n=38,39,38,39,30,32012250
SecondaryChange From Baseline in Immunoglobin (Ig) A, IgG and IgM Levels

Blood samples were collected to evaluate change from Baseline in IgA, IgG, IM values at Baseline throughout the 12 weeks of study treatment. Baseline values were taken at Day 1 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

Time frame:
Week, 4, 8 and 12
Reported as:
Mean · G/L
Change From Baseline in Immunoglobin (Ig) A, IgG and IgM Levels
G/LGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
IgA; Week 4; n= 37,38,38,38,30,32-0.016 ± 0.2528-0.103 ± 0.2108-0.079 ± 0.2003-0.026 ± 0.2342-0.046 ± 0.2179-0.045 ± 0.3141
IgA; Week 8; n= 35,37,34,38,29,28-0.064 ± 0.2558-0.116 ± 0.2314-0.056 ± 0.25700.035 ± 0.21880.026 ± 0.2695-0.036 ± 0.3106
IgA; Week 12; n= 36,37,32,35,28,27-0.056 ± 0.2820-0.099 ± 0.6148-0.140 ± 0.2207-0.042 ± 0.2657-0.038 ± 0.1744-0.016 ± 0.2462
IgG; Week 4; n= 37,38,38,38,30,32-0.130 ± 1.0945-0.446 ± 0.8854-0.282 ± 1.2618-0.347 ± 1.1148-0.198 ± 1.2753-0.112 ± 1.1564
IgG; Week 8; n= 35,37,34,38,29,28-0.007 ± 1.2785-0.457 ± 1.0787-0.121 ± 1.4233-0.200 ± 1.14490.428 ± 1.19840.203 ± 1.4037
IgG; Week 12; n= 36,37,32,35,28,27-0.033 ± 1.2978-0.436 ± 3.8561-0.367 ± 1.0214-0.269 ± 0.92390.256 ± 1.59150.331 ± 0.8796
IgM; Week 4; n=37,38,38,38,30,32-0.049 ± 0.1524-0.102 ± 0.1514-0.077 ± 0.0968-0.043 ± 0.1303-0.052 ± 0.0933-0.040 ± 0.0886
IgM; Week 8; n= 35,37,34,38,29,28-0.070 ± 0.1069-0.095 ± 0.1314-0.111 ± 0.1290-0.052 ± 0.1167-0.014 ± 0.1396-0.040 ± 0.0956
IgM; Week 12; n= 36,37,32,35,28,27-0.055 ± 0.1852-0.098 ± 0.1955-0.125 ± 0.1233-0.072 ± 0.1112-0.047 ± 0.1300-0.034 ± 0.0850
SecondaryNumber of Participants With Immunoglobulin Data Outside the Reference Range

Blood samples were collected from participants for evaluation of immunoglobulin data outside the reference range at Baseline, Week 4, Week 8, Week 12 and any visit post-screen. The immunoglobulin parameters included IgA, IgG and Ig M. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Time frame:
Baseline, Week, 4, 8, 12, post-screen (up to Week 16)
Reported as:
Number · Participants
Number of Participants With Immunoglobulin Data Outside the Reference Range
ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
IgA; Baseline; n= 40,41,43,41,42,40232142
IgA; Week 4; n= 37,38,38,38,30,32223032
IgA; Week 8; n= 35,37,34,38,29,28213212
IgA; Week 12; n= 36,37,32,35,28,27314112
IgA; post-screen; n= 38,39,38,39,30,32434233
IgG; Baseline; n=40,41,43,41,42,40251433
IgG; Week 4; n= 37,38,38,38,30,32130332
IgG; Week 8; n=35,37,34,38,29,28330342
IgG; Week 12; n=36,37,32,35,28,27450542
IgG; post screen; n= 38,39,38,39,30,32460563
IgM;Baseline; n= 40,41,43,41,42,40473364
IgM; Week 4; n=37,38,38,38,30,32356126
IgM; Week 8; n= 35,37,34,38,29,28347335
IgM; Week12; n= 36,37,32,35,28,27457236
IgM; post-screen; n=38,39,38,39,30,324510436
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

SBP and DBP were measured from Baseline up to follow up Visit 1 at Week 14 in semi-supine position after at least 5 minutes of rest. The Baseline value was taken at Day 1 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

Time frame:
Week 1, 2, 4, 8, 12, 14, EW (up to week 14)
Reported as:
Mean · Millimeter of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeter of mercury (mmHg)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
SBP; Week 1; n= 38,31,39,37,38,33-1.6 ± 8.89-2.3 ± 11.02-2.3 ± 14.72-1.9 ± 9.770.8 ± 9.32-0.7 ± 9.45
SBP; Week 2; n=39,39,39,39,33,32-1.7 ± 12.220.6 ± 10.57-4.3 ± 13.37-1.2 ± 11.41-0.8 ± 10.41-1.6 ± 6.90
SBP; Week 4; n= 38,39,38,39,30,32-1.7 ± 10.570.5 ± 10.00-3.8 ± 9.05-1.8 ± 11.941.9 ± 13.33-0.5 ± 14.24
SBP; Week 8; n= 36,37,34,38,29,28-1.9 ± 10.74-0.5 ± 11.27-4.3 ± 11.38-1.9 ± 9.860.0 ± 11.291.0 ± 17.08
SBP; Week 12; n= 36,37,32,35,28,28-3.1 ± 10.28-0.1 ± 11.64-1.9 ± 12.62-2.4 ± 10.71-0.5 ± 10.44-0.5 ± 12.67
SBP; Week 14; n=34,35,32,34,31,29-1.0 ± 11.95-0.5 ± 12.52-1.4 ± 12.76-1.9 ± 9.461.2 ± 13.180.3 ± 11.29
SBP; EW; n= 3,4,7,3,11,115.3 ± 8.08-5.3 ± 18.014.9 ± 13.63-0.7 ± 7.371.2 ± 8.812.0 ± 6.96
DBP; Week 1; n=38,31,39,37,38,33-2.0 ± 8.551.4 ± 8.48-1.9 ± 8.74-1.5 ± 7.331.1 ± 9.29-0.4 ± 7.53
DBP; Week 2; n=39,39,39,39,33,32-3.4 ± 9.600.1 ± 8.14-3.7 ± 7.63-3.3 ± 7.07-2.2 ± 10.29-0.9 ± 5.97
DBP; Week 4; n=38,39,38,39,30,32-3.0 ± 12.210.9 ± 7.98-3.1 ± 9.31-4.0 ± 7.98-0.1 ± 10.491.9 ± 9.18
DBP; Week 8; n=36,37,34,38,29,28-4.8 ± 9.791.0 ± 8.07-3.3 ± 9.24-2.1 ± 8.91-0.2 ± 10.102.2 ± 10.08
DBP; Week 12; n= 36,37,32,35,28,28-6.5 ± 8.862.6 ± 7.02-2.8 ± 8.82-4.0 ± 9.180.9 ± 9.811.3 ± 8.93
DBP; Week 14; n= 34,35,32,34,31,29-5.6 ± 9.23-0.5 ± 7.71-2.9 ± 9.10-0.4 ± 8.49-0.4 ± 9.450.9 ± 7.75
DBP; EW; n= 3,4,7,3,11,113.3 ± 3.061.3 ± 3.400.0 ± 10.82-1.0 ± 9.542.3 ± 3.66-2.7 ± 7.02
SecondaryChange From Baseline in Pulse Rate

Pulse rate were measured from Baseline up to follow up Visit 1 at Week 14 in semi-supine position after at least 5 minutes of rest. The Baseline value was taken at Day 1 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

Time frame:
Week 1, 2, 4, 8, 12, 14, EW (up to week 14)
Reported as:
Mean · Beats per minute (bpm)
Change From Baseline in Pulse Rate
Beats per minute (bpm)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1; n= 38,41,39,37,38,335.8 ± 9.192.5 ± 8.680.8 ± 10.19-0.4 ± 9.390.4 ± 9.43-0.4 ± 9.82
Week 2; n= 39,39,39,39,33,323.7 ± 10.672.3 ± 10.900.1 ± 9.631.0 ± 10.901.5 ± 11.991.0 ± 10.47
Week 4; n= 38,39,38,39,30,326.2 ± 10.020.6 ± 10.79-0.3 ± 12.300.4 ± 10.88-1.7 ± 11.670.1 ± 8.42
Week 8; n= 36,37,34,38,29,284.1 ± 9.720.6 ± 10.27-1.7 ± 9.593.2 ± 11.23-0.2 ± 11.450.8 ± 8.97
Week 12; n= 36,37,32,35,28,283.0 ± 10.03-0.0 ± 11.550.0 ± 10.080.4 ± 9.74-1.9 ± 9.581.3 ± 10.76
Week 14; n= 34,35,32,34,31,293.3 ± 9.383.5 ± 11.650.6 ± 10.002.5 ± 10.970.8 ± 11.060.7 ± 8.56
EW; n= 3,4,7,3,11,11-13.7 ± 1.150.3 ± 3.50-6.0 ± 9.83-2.7 ± 8.964.2 ± 12.18-0.5 ± 9.15
SecondaryChange From Baseline in Temperature

Temperature were measured from Baseline up to follow up Visit 1 at Week 14 in semi-supine position after at least 5 minutes of rest. The Baseline value was taken at Day 1 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and SD were measured.

Time frame:
Week 1, 2, 4, 8, 12, 14, EW (up to week 14)
Reported as:
Mean · Degree Celsius
Change From Baseline in Temperature
Degree CelsiusGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1; n= 38,41,39, 37,38,330.013 ± 0.3640-0.056 ± 0.26180.015 ± 0.3689-0.006 ± 0.3932-0.053 ± 0.7928-0.024 ± 0.2693
Week 2; n=39,39,39,39,32,32-0.054 ± 0.4973-0.064 ± 0.26800.005 ± 0.3332-0.069 ± 0.4691-0.097 ± 0.70820.016 ± 0.2841
Week 4; n= 38,39,38,39,30,32-0.074 ± 0.4428-0.023 ± 0.3256-0.013 ± 0.3458-0.068 ± 0.4902-0.030 ± 0.67060.013 ± 0.2459
Week 8; n= 36,37,34,38,29,280.006 ± 0.4276-0.024 ± 0.2671-0.056 ± 0.32950.045 ± 0.40110.062 ± 0.75660.021 ± 0.3304
Week 12; n=36,37,32,35,28,280.003 ± 0.4212-0.068 ± 0.3292-0.078 ± 0.2814-0.040 ± 0.45320.043 ± 0.76180.004 ± 0.4574
Week 14;n=34,35,32,34,31,29-0.079 ± 0.4059-0.131 ± 0.6416-0.059 ± 0.3618-0.109 ± 0.4876-0.013 ± 0.8740-0.052 ± 0.3582
EW; n= 3,4,7,3,11,11-0.033 ± 0.15280.000 ± 0.36510.100 ± 0.25170.400 ± 0.5568-0.182 ± 0.52120.164 ± 0.4985
SecondaryNumber of Participants With Vital Signs of Potential Clinical Importance

Blood samples were collected from participants for evaluation of vital signs by Potential Clinical Importance Criteria from Baseline to Week 14, EW and any visit post-screen. The vital signs included SBP, DBP and pulse rate. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Time frame:
Baseline, Week 2, 4, 8, 12, 14, EW (up to week 14)
Reported as:
Number · Participants
Number of Participants With Vital Signs of Potential Clinical Importance
ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
SBP; Baseline; n= 40,41,43,41,42,40000001
SBP; Week 1; n= 38,41,39,37,38,33110000
SBP; Week 2; n= 39,39,39,39,33,32000201
SBP; Week 4; n= 38,39,38,39,30,32000101
SBP; Week 8; n= 36,37,34,38,29,28000002
SBP; Week 12; n= 36,37,32,35,28,28011101
SBP: Week 14; n= 34,35,32,34,31,29000201
SBP; EW; n= 3,4,7,3,11,11000000
SBP; post-screen; n= 40,41,43,41,42,40121303
DBP; Baseline; n= 40,41,43,41,42,40001000
DBP; Week 1; n=38,41,39,37,38,33000000
DBP; Week 2; n=39,39,39,39,33,32000010
DBP; Week 4; n=38,39,38,39,30,32000001
DBP; Week 8; n= 36,37,34,38,29,28000111
DBP; Week 12; n= 36,37,32,35,28,28000110
DBP; Week 14; n= 34,35,32,34,31,29000100
DBP; EW; n= 3,4,7,3,11,11100000
DBP; post-screen; n= 40,41,43,41,42,40101112
Pulse rate; Baseline; n= 40,41,43,41,42,40000000
Pulse rate; Week 1; n= 38,41,39,37,38,33000000
Pulse rate;Week 2; n= 39,39,39,39,33,32000000
Pulse rate; Week 4; n= 38,39,38,39,30,32000100
Pulse rate; Week 8; n= 36,37,34,38,29,28000000
Pulse rate; Week 12; n= 36,37,32,35,28,28000000
Pulse rate; Week 14; n= 34,35,32,34,31,29011000
Pulse rate; EW; n= 3,4,7,3,11,11000000
Pulse rate; post-screen; n=40,41,43,41,42,40011100
SecondaryNumber of Participants With Abnormal Electrocardiogram (ECG) Findings

Single measurements of 12-lead ECGs were obtained at Baseline , Week 1, Week 12, Week 14 (follow up 1), EW and at any time post-screen using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc). Baseline was defined as the latest assessment prior to the first dose. For multiple ECGs at one visit, or "Any visit post-screen", a participant was categorized as "Abnormal" if \>=1 assessment was abnormal. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline, Week 1, 12, 14, EW ( up to Week 14), post-screen
Reported as:
Number · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Baseline; n= 40,41,43,41,42,40864555
Week 1; n= 37,41,39,37,38,33884556
Week 12; n= 36,37,32,35,28,28764314
Week 14; n= 34,34,32,34,31,29845615
EW; n= 3,3,7,3,10,11010201
post-screen; n= 40,41,41,39,41,4012105859

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study treatment until the Folow up Visit 2 at Week 16.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK2894512 1% Cream Twice Daily0/40 (0%)1/40 (2.5%)28/40 (70%)
GSK2894512 1% Cream Once Daily0/41 (0%)0/41 (0%)22/41 (53.7%)
GSK2894512 0.5% Cream Twice Daily0/43 (0%)0/43 (0%)20/43 (46.5%)
GSK2894512 0.5% Cream Once Daily0/41 (0%)0/41 (0%)23/41 (56.1%)
Vehicle Cream Twice Daily0/42 (0%)0/42 (0%)19/42 (45.2%)
Vehicle Cream Once Daily0/40 (0%)0/40 (0%)15/40 (37.5%)
Most frequent serious events
Most frequent serious events
EventGSK2894512 1% Cream Twice DailyGSK2894512 1% Cream Once DailyGSK2894512 0.5% Cream Twice DailyGSK2894512 0.5% Cream Once DailyVehicle Cream Twice DailyVehicle Cream Once Daily
AnxietyPsychiatric disorders1/400/410/430/410/420/40
Attention deficit /hyperactivity disorderPsychiatric disorders1/400/410/430/410/420/40
Most frequent other events
Showing 10 of 106
Most frequent other events
EventGSK2894512 1% Cream Twice DailyGSK2894512 1% Cream Once DailyGSK2894512 0.5% Cream Twice DailyGSK2894512 0.5% Cream Once DailyVehicle Cream Twice DailyVehicle Cream Once Daily
FolliculitisInfections and infestations4/408/413/433/410/420/40
Dermatitis atopicSkin and subcutaneous tissue disorders2/400/413/431/414/425/40
NasopharyngitisInfections and infestations3/405/414/431/414/423/40
Upper respiratoryInfections and infestations4/402/413/432/413/421/40
HeadacheNervous system disorders4/401/411/433/410/422/40
ImpetigoInfections and infestations1/400/410/430/410/423/40
AcneSkin and subcutaneous tissue disorders2/400/411/433/411/420/40
DiarrhoeaGastrointestinal disorders1/401/410/432/410/420/40
Application site painGeneral disorders1/400/411/430/412/421/40
BronchitisInfections and infestations0/400/412/430/410/420/40

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QDTotal
Mean28.5 ± 13.9031.6 ± 15.7229.0 ± 15.9129.3 ± 14.0227.9 ± 14.7229.4 ± 15.1529.3 ± 14.83
Sex: Female, Male
Sex: Female, Male(Participants)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QDTotal
Female182417222317121
Male221726191923126
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QDTotal
Race/Ethnicity, Customized — White/Caucasian161817172012100
Race/Ethnicity, Customized — Black/African American710111261258
Race/Ethnicity, Customized — American Indian/Alaska Native0001001
Race/Ethnicity, Customized — Asian/S.E. Asian Descent/Japanese15131310151480
Race/Ethnicity, Customized — American Indian/Alaska Native and African American0001001
Race/Ethnicity, Customized — Asian/S.E. Asian/Japanese and African American1010002
Race/Ethnicity, Customized — Asian/S.E. Asian/Japanese and Black and White0010001
Race/Ethnicity, Customized — Asian/S.E. Asian/Japanese and White/Caucasian0000011
Race/Ethnicity, Customized — Black/African American and White/Caucasian1000113
08

Study locations

60 sites
  • GSK Investigational Site
    Fort Smith, Arkansas 72916, United States
  • GSK Investigational Site
    Fresno, California 93720-2933, United States
  • GSK Investigational Site
    Irvine, California 92697, United States
  • GSK Investigational Site
    Los Angeles, California 90045, United States
  • GSK Investigational Site
    Oceanside, California 92056, United States
  • GSK Investigational Site
    Santa Ana, California 92701, United States
  • GSK Investigational Site
    Denver, Colorado 80220, United States
  • GSK Investigational Site
    North Logan, Connecticut 06032, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Chicago, Illinois 60611, United States
  • GSK Investigational Site
    Dundee, Illinois 60118, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46256, United States
  • GSK Investigational Site
    New Albany, Indiana 47150, United States
  • GSK Investigational Site
    Overland Park, Kansas 66215, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70115, United States
  • GSK Investigational Site
    Andover, Massachusetts 01810, United States
  • GSK Investigational Site
    Bay City, Michigan 48706, United States
  • GSK Investigational Site
    West Bloomfield Township, Michigan 48322, United States
  • GSK Investigational Site
    Fridley, Minnesota 55432, United States
  • GSK Investigational Site
    Saint Joseph, Missouri 64506, United States
  • GSK Investigational Site
    New York, New York 10022, United States
  • GSK Investigational Site
    High Point, North Carolina 27262, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45255, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19103, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • GSK Investigational Site
    Cranston, Rhode Island 2910, United States
  • GSK Investigational Site
    Greer, South Carolina 29650, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Dallas, Texas 75231, United States
  • GSK Investigational Site
    Houston, Texas 77004, United States
  • GSK Investigational Site
    Houston, Texas 77056, United States
  • GSK Investigational Site
    San Antonio, Texas 78218, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Webster, Texas 77598, United States
  • GSK Investigational Site
    Norfolk, Virginia 23507, United States
  • GSK Investigational Site
    Seattle, Washington 98101, United States
  • GSK Investigational Site
    Surrey, British Columbia V3R 6A7, Canada
  • GSK Investigational Site
    Markham, Ontario L3P1X2, Canada
  • GSK Investigational Site
    Oakville, Ontario L6J 7W5, Canada
  • GSK Investigational Site
    Ottawa, Ontario K2G 6E2, Canada
  • GSK Investigational Site
    Peterborough, Ontario K9J5K2, Canada
  • GSK Investigational Site
    Richmond Hill, Ontario L4B 1A5, Canada
  • GSK Investigational Site
    Waterloo, Ontario N2J 1C4, Canada
  • GSK Investigational Site
    Windsor, Ontario N8W 5L7, Canada
  • GSK Investigational Site
    Drummondville, Quebec J2B 5L4, Canada
  • GSK Investigational Site
    Quebec City, Quebec G1V4X7, Canada
  • GSK Investigational Site
    Fukuoka, 813-0044, Japan
  • GSK Investigational Site
    Fukuoka, 819-0373, Japan
  • GSK Investigational Site
    Hokkaido, 003-0026, Japan
  • GSK Investigational Site
    Hokkaido, 006-0022, Japan
  • GSK Investigational Site
    Kanagawa, 211-0063, Japan
  • GSK Investigational Site
    Kanagawa, 220-0004, Japan
  • GSK Investigational Site
    Kanagawa, 221-0825, Japan
  • GSK Investigational Site
    Kumamoto, 861-3101, Japan
  • GSK Investigational Site
    Osaka, 572-0838, Japan
  • GSK Investigational Site
    Osaka, 593-8324, Japan
  • GSK Investigational Site
    Tokyo, 133-0057, Japan
  • GSK Investigational Site
    Tokyo, 169-0075, Japan
  • GSK Investigational Site
    Tokyo, 194-0013, Japan
  • GSK Investigational Site
    Tokyo, 203-0003, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Jan 2017 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2017, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2015
First posted
Sep 30, 2015
Start
Dec 1, 2015
Primary completionActual
Jan 1, 2017
CompletionActual
Jan 12, 2017
Results first posted
Nov 20, 2017
Last update
Nov 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02564055
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 30, 2015
Start date
Dec 1, 2015
Primary completion
Jan 1, 2017
Completion
Jan 12, 2017
Results posted
Nov 20, 2017
Last update
Nov 20, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tapinarof

Start the discussion